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ABSTRACT 
Sub-Saharan Africa is a high endemicity region of both Hepatitis B Virus (HBV) and Human 
Immunodeficiency Virus (HIV) infection. There is a paucity of information in this highly 
endemic region on molecular evolution of HBV in HIV-infected individuals receiving long-
term Lamivudine (Lam) therapy. This study aimed at characterizing the molecular evolution 
of HBV in HIV-infected black Southern Africans prior-to the initiation of a Lam- containing 
antiretroviral (ARV) drug regimen, and 3, 6, 12 and 18 months post-initiation. HBV viral-
loads were quantified using real-time PCR and used to determine the viral suppression in 39 
participants from the Shongwe Hospital in rural Mpmualanga, Republic of South Africa. The 
study participants included 16 participants who were HBsAg+ and 23 HBsAg- at baseline. Of 
the HBsAg- participants, 19 remained negative throughout follow-up these were defined as 
the HBsAg- group. The remaining 20 participants were HBsAg+ at baseline and/or at one 
time-point during follow-up, are referred to as the HBsAg+ group, nine were HBsAg+ 
throughout the study. Seven participants sero-converted to HBsAg- at a median of 4.2 
months, two participants gained the HBsAg at 18.3 months. Two participants were HBsAg- 
at baseline, thereafter became sero-positive but had retro-converted to HBsAg- by last time-
point. A significant finding between these two HBsAg serological groups, was a higher viral 
suppression achieved in the HBsAg- group -100%, with the HBsAg+ group achieving 
13.54% HBV suppression (p = 0.01).  HBV was fully suppressed in ten participants, with no 
suppression found in the remaining participants 29, of which 10 experienced a virologic 
breakthrough (VBT). HBsAg-negativity was a predictor of viral suppression, with ten 
HBsAg-negative participants achieving full suppression of HBV (p = 0.01). The NS VBT+ 
group had a significantly higher percentage of viral suppression, 51,90%,  compared to the 
NS VBT- group 14,35%, despite the VBT events (p = 0.03). Biochemical analysis revealed 
that baseline alanine transferase (ALT) levels were significantly lower in the full suppression 
(FS) group indicating that lower ALT levels are a predicator of viral suppression (p = 0.02). 
Participants in the FS group had significantly lower ALT levels (15.5) at baseline compared 
to the NS group (35) (p=0.02).  Another finding of the study was that only participants 
belonging to the HBsAg-negative group were able to clear the HBV virus whereas HBsAg 
positivity at any time point precluded clearance of HBV DNA. The Basal Core 
Promotor/PreCore (BCP/PreC) and complete surface (S) regions were amplified and 
sequenced to genotype HBV isolated from this cohort, as well as find detection or immune 
escape mutations. The majority of HBV isolates belonged to subgenotype A1, with the 
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exception of two baseline isolates that belonged to genotype E and subgenotype D3, 
respectively.  Various mutations were found in the 61 BCP/PreC region sequences (T1753C, 
A1762T G1764A, Kozak sequence, G1862T, G1896A) that could account for the high 
prevalence of HBeAg-negative infections observed at the various time-points. These 
mutations can lead to the down regulation of PreC mRNA transcription or translation, and/or 
affect post-translational modification of HBeAg. Amplification of the complete S-region and 
overlapping Polymerase regions yielded 47 sequences. Twenty-three of these sequences were 
from baseline samples, and the remaining from follow-up time-points.  PreS deletions 
involved in the development of HCC were found in two follow-up isolates. These deletions, 
and other immune or detection escape mutations found in the S region, may contribute to the 
HBsAg negativity found in this study. In conclusion ALT levels and HBsAg status at 
baseline were predictors of the outcome of HBV suppression in response to anti-retroviral 
therapy. This study adds to the limited information available on the molecular changes 
observed in HBV isolates in HIV-infected South Africans under selection pressure from Lam. 
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CHAPTER 1: INTRODUCTION 
 
With a genome of 3.2 kilobase (kb), hepatitis B virus (HBV) is the smallest DNA 
virus infecting humans. A vaccine against HBV was developed in the early 
1980’s, however, three decades later the world’s population is still heavily 
burdened by this hepatotropic pathogen and the diseases associated with it, 
namely hepatitis, decompensated cirrhosis, end-stage liver disease (ESLD) and  
hepatocellular carcinoma (HCC) (Lavanchy, 2004; Gerlich, D). These HBV-
related complications result in 786 000 deaths annually (Stanaway et al., 2016), 
posing a major public health problem (Rantala and de Laar, 2008). The public 
health risk posed by HBV is further exacerbated by the development of drug-
resistant and vaccine-escape mutants of the virus (Glebe and Urban, 2007). 
 
For a number of reasons, HBV infection is a major problem in sub-Saharan 
Africa.  Firstly, sub-Saharan Africa unlike other high HBV endemicity regions did 
not have a vaccine catch-up programme (Spearman et al., 2013). Secondly, 
theHBV burden is compounded by the high prevalence of Human 
Immunodeficiency Virus (HIV) infections in this region. Of the 34 million HIV-
infected persons globally, approximately two-thirds are found in sub-Saharan 
Africa, with HBV-HIV co-infections rates of up to10% (Matthews et al., 2014). 
Thirdly, anti-retroviral treatment (ART) containing lamivudine (3TC), which also 
acts against HBV, has been widely used in sub-Saharan Africa to treat HIV-
infected individuals(Hoffmann et al., 2008).Lamivudine treatment can result in 
the development of drug resistant mutations in 80% of patients after 5 years of 
treatment(Fasano et al., 2012) leading to reactivation of asymptomatic HBV.  
Thus the introduction of ART, has resulted in a changed disease profile, with an 
increase in HBV-associated ESLD (Thomas, 2006). Therefore it is important that 
HBV in HIV infected individuals is studied especially after ART.   
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1.1 Epidemiology 
 
Globally there are an estimated 2 billion people with past or present HBV 
infection, with 240 million chronic carriers of HBV (Hepatitis B Fact sheet no 
204. http://www.who.int/mediacentre/factsheets/fs204/en/ October 2015).  
Serological evidence of HBVinfection is measured by hepatitis B Surface Antigen 
(HBsAg) positivity and is used to discern between geographical areas of low (< 
2%), intermediate (2 - 8%) and high (> 8%) endemicity (Hou et al., 2005). Areas 
of low endemicity are the United States of America, Northern Europe, Australia 
and parts of South America. Intermediate endemicity regions include the Middle 
East, Eastern Europe and the Mediterranean basin. HBV is most prevalent (>5-
10%) in sub-Saharan Africa, southern-eastern Asia, the Balkan regions, Pacific 
Islands and the Amazon basin (Figure 1.1) (Sunbul, 2014).  More than half the 
world’s population reside within highly endemic regions with 5-10% of these 
populations burdened by chronic hepatitis B (CHB)(Schweitzer et al., 2015; 
World Health Organisation, 2016). There are approximately 4 million cases of 
acute infections annually and a low 0.5- 1% fatality rate (Lavanchy, 2004). Acute 
infection leads to chronic infection in 90% of neonates, 20 - 60% of children 
under the age of 5 years and < 5% of adults (McMahon, 2004).  
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Figure 1.1 Global overview of low, intermediate and high HBV endemicity 
regions. Areas of high endemicity (pink), intermediate endemicity (varying 
shades of blue, low intermediate-light blue, high intermediate-dark blue), low 
endemicity (pale blue) (Hou et al., 2005; Lavanchy and Kane, 2016) 
 
 
1.2 Transmission 
HBV is transmitted through various routes such as unprotected sexual contact, 
percutaneously by intravenous drug (IVD) use, perinatally (vertically), 
horizontally, during transfusion of blood products, needle-stick injury and hepatic 
or extra-hepatic organ transplantation (Mauss et al., 2014). Routes of transmission 
differ, between different geographic locations, also between genotypes (Hou et 
al., 2005).  
 
Sexual transmission is most common in areas of low prevalence, 25% of these 
infections are transmitted by men who have sex with men (MSM) (Edmunds et 
al., 1996). In high endemicity areas, the mode of HBV transmission is either 
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vertical or horizontal (Davis, Weber and Lemon, 1989). Perinatal transmission is 
predominant in Asia, occurring either in utero, peri-partum or post-partum 
(Merican et al., 2000). In sub-Saharan Africa horizontal transmission during 
childhood, accounts for majority of infections through parenteral contact among 
family members or unrelated children (Kramvis and Kew 2007; Anigilaje and 
Olutola 2013). Intravenous drug use (IVDU) is the most prevalent type of 
percutaneous transmission (Hoffmann and Thio, 2007),  however, acupuncture, 
tattooing, scarification, body piercing, sharing of razors or toothbrushes, play a 
role in transmission. HBV is the most transmitted blood borne virus in the 
healthcare industry (Mauss et al., 2014). HBV and HIV share transmission routes 
namely: vertical, parenteral and sexual (Davis, Weber and Lemon, 1989; Dabis 
and Ekpini, 2002) 
 
 
1.3 Hepatitis B Virus  
1.3.1 Classification of HBV 
HBV is a hepatotropic DNA virus belonging to the familyHepadnaviridae, of 
which it is the prototype virus.  Members of this family are double-stranded DNA 
viruses but replicate as pararetroviruses using a single-stranded RNA-intermediate  
(Robinson, Miller and Marion, 1987). This family consists of two genera: 
Orthohepadnaviruses (infecting mammals) and Avihepadnaviruses (infecting 
birds).  Orthohepdnaviruses have been found in humans (HBV), bats (BHBV) 
(Drexler et al. 2013), ground squirrels (GSHV) (Marion et al., 1980), artic 
squirrels (ASHV) (Testut et al., 1996), woolly monkeys (WMHV) (Lanford et al., 
1998), woodchucks (WHV) (Summers, Smolec and Snydert, 1978), chimpanzees 
(CHV) (Vaudin et al., 1988; Zuckerman et al., 2016), gorillas (GoHBV) (Grethe, 
Heckel and Rietschel, 2000), gibbons (GiHBV) (Norder et al., 1996; Grethe, 
Heckel and Rietschel, 2000), baboons (Dickens et al., 2013)and orangutans 
(OuHV) (Warren, Heeney and Swan, 1999). Avihepadnaviruses have been found 
in ducks (DHBV) (Mason, Seal and Summers, 1980), herons (HHBV) (Sprengel, 
Kaleta and Will, 1988), snow geese (SGHBV) (Chang et al., 1999), Ross’s geese 
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(RGHBV) (Pult et al., 2001), storks (STHBV) (Pult et al., 2001; Prassolov et al., 
2003) and cranes (CHBV) (Prassolov et al., 2003).  
 
 
DHBV and WHV have been used to study hepadnaviral replication and chronic 
liver disease (Seeger and Mason, 2000)whereas WHV and GSHV are the closest 
relatives of HBV (Marion et al., 1980). HBV solely infects humans and 
chimpanzees, and chimpanzees are purposely infected and used as a model to 
study HBV (Maynard et al., 1972; Barker et al., 1973; Sureau, 1993). However, 
recent findings of HBV in bats indicate that BHBV has the ability to infect 
humans (Drexler et al., 2013).  
 
 
1.3.2 HBV Structure and Biology 
1.3.2.1 HBV Viral Structure 
Hepatitis B virus has three types of structures, the infectious Dane particle and 
two sub-viral particles (SVPs): the filamentous and spherical particles (Figure 
1.2), (Bayer, Blumberg and Werner, 1968; Dane, Cameron and Briggs, 1970). The 
sub-viral particles do not contain DNA rendering them non-infectious.  The 
spherical particle is  ̴ 22 nm in diameter, the filamentous particles shares a similar 
width but may be of variable length (Glebe and Urban, 2007). The SVPs act as a 
decoy for the neutralising anti-HBs, allowing immune evasion of the infectious 
Dane particles (Chen et al., 2005). SVPs vastly outnumber Dane particles in ratios 
of 1000:1 up to 10 000:1 (Scaglioni, Melegari and Wands, 1996). All three types 
of HBV particles contain viral surface proteins.  The Dane particle is enclosed by 
an envelope comprised oflipid membranes, which are not acquired from the host 
plasma-membrane but from the lipid membranes of the host’s intracellular 
compartments (Glebe and Urban, 2007). The mechanism of assembly of SVPs 
differs from that of Dane particles (Tiollais, Pourcel and Dejean, 1985). 
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Figure 1.2 Dane Particles, filamentous and spherical sub-viral particles: the 
black and red double-circular structure represents the Dane particle indicating the 
Hepatitis B surface Antigen (HBsAg) and the Hepatitis B core Antigen (HBcAg). 
The PreS1 and PreS2 domains of Large HBV surface Protein (LHBs) embedded 
in the viral capsid are indicated on the Dane particle. The LHBs, Medium HBV 
surface protein (MHBs) and Small HBV surface protein (SHBs) demonstrate the 
surface proteins found on both the Dane and sub-viral particles (Gerlich, 2013). 
Reproduced in accordance with the Open Data Policy of Biomed Central and the 
Creative Commons CC1.0 Public Domain Dedication Waiver 
 
 
Dane particles (Figure 1.3) are spherical, double-layered structures of 40 – 44 nm 
in diameter (Dane, Cameron and Briggs, 1970). The outer layer is made-up of 
host-derived lipids and randomly distributed surface proteins. The inner-layer or 
nucleocapsid is an icosahedral structure of densely packed HBV core proteins, 
containing a single copy of partially double-stranded relaxed circular DNA (ds 
rcDNA) (Summers, O’Connell and Millman, 1975; Robinson, Miller and Marion, 
1987). 
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Figure 1.3 HBV Dane particle: Illustration Copyright James A. Perkins. Used 
with permission. 
 
 
1.3.2.2 HBV Genome Organisation 
The nucleocapsid envelops a 3200 base pair (bp) closed circular DNA (size of 
genome varies with genotype) comprising of a complete minus-strand and an 
incomplete (50 - 75% complete) plus-strand (Lutwick and Robinson, 1977; 
Summers, 1987). Numbering of the HBV genome begins at the EcoR1 site, 
henceforth, this will be the system used when referring to nucleotide positions. A 
polymerase molecule is covalently bound to the 5’- end of the minus-strand using 
a phosphotyrosine bond (Gerlich and Robinson, 1980; Nassal, 2008). An 18 
nucleotide (nt) ribonucleic acid (RNA) oligomer, the pre-genomic RNA 
(pgRNA), essential for replication, is found at the 5’-end of the positive strand. 
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Two redundant DNA sequences of eight nt, essential for DNA replication, are 
found at both the 5’ - and 3’- ends of the minus strand, these direct repeats (DR) 
are referred to as DR1 and DR2 (Seeger, Ganem and Varmus, 1986; Nassal, 
2008). The integrity of the circular DNA structure is maintained by base-pairing 
between the minus- and plus-strands rather than covalent bonding (Tiollais, 
Pourcel and Dejean, 1985).  
 
 
Despite HBV being the smallest DNA virus infecting humans, it makes efficient 
use of its compact genome by producing seven proteins from four partially 
overlapping Open Reading Frames (ORFs), with the entire genome being 
involved in coding (Tiollais, Pourcel and Dejean, 1985). Six start codons, four 
promoters (Core, PreS1, PreS2/S and X) and two enhancers (EnhI and EnhII) are 
found within the coding regions (Moolla, Kew and Arbuthnot, 2002). The four 
ORFs are in the same orientation and use a common polyadenylation signal to 
terminate transcription (Seeger and Mason, 2000).    
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Figure 1.4 HBV genome organisation: Indicating the complete minus-strand and 
incomplete plus-strand, also represented are the four ORFs which code for all 
seven HBV proteins. Surface (S), polymerase, PreC/Core and x genes and their 
co-ordinates are represented by the coloured fragments. YMDD, an important 
amino-acid sequence within the reverse-transcriptase protein; RNA primer, the 18 
nt RNA oligomer found at 5’-end of the plus-strand and the polymerase molecule 
(orange oval structure) bound to the 5’-end of the minus-strand. Direct repeats 
(DR1&2).(Hunt et al., 2000) Reproduced with permission from John Wiley and 
Sons ©, 2001.  
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1.3.3 Viral Proteins  
The PreS/S ORF codes for three structural or envelope proteins, are named 
according to their size; Large, Medium and Small Hepatitis B Surface proteins 
(LHBs, MHBs and SHBs, respectively). The PreCore/Core (PreC/C) ORF codes 
for; the secretory Hepatitis B ‘early’ (or ‘envelope’) antigen (HBeAg) and the 
structural nucleocapsid protein referred to as Hepatitis B core antigen (HBcAg). 
The polymerase (Pol) and x-ORF encode, the multifunctional polymerase enzyme 
and  x-protein, respectively (Heermann et al., 1984). Four mRNA transcripts, the 
pregenomic (3.5 kb), PreS1 (2.4 kb), PreS2/S (2.1 kb) and x (0.7 kb) mRNAs are 
used to produce the seven proteins. 
 
 
1.3.3.1 Viral Surface Proteins  
The S-gene has three start codons and a common stop codon (UAA) at the 3’- end 
(Seeger and Mason, 2000). The PreS/S ORF codes for three viral surface proteins, 
LHBs, MHBs and SHBs, found on the membrane of Dane particles and SVPs 
(Heermann et al., 1984). Surface proteins are synthesised in the Endoplasmic 
Reticulum (ER) (Le Seyec et al., 1999), vastly outnumbering the amount required 
for mature virion synthesis (Heermann et al., 1984; Bruss and Ganem, 1991). 
Surface proteins are glycosylated or unglycosylated (Stibbe and Gerlich, 1983), 
however all contain SHBs-domains, also known as HBsAg. The crucial antigenic 
‘a’ determinant site is found within the SHBs region of all HBV surface proteins 
(Sanchez et al., 1981).     
 
 
1.3.3.1.1 LHBs: coded for by nt 2848 - 835, LHBs (42kDa) uses the 2.4 kb PreS1 
mRNA transcript to produce a 389 - 400 amino acid (aa) protein (aa length is 
dependent on genotype) (Heermann et al., 1984). The PreS1, PreS2 and S-
domains constitute the LHBs molecule and the PreS1-domain is unique to this 
protein. During synthesis the LHBs protein is found either exposed to the 
cytoplasm of the host-cell or is projected into the lumen of the ER, therefore two 
topological variations of LHBs occur (Bruss and Ganem, 1991; Glebe and Urban, 
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2007). Those exposed into the cytoplasm are used to provide an attachment site 
for the nucleocapsid core protein molecules during virion maturation, allowing the 
nucleocapsid to bind or anchor to the outer viral capsid (Prange and Streeck, 
1995). The LHBs projecting into the ER lumen becomes exposed on the surface 
of the virion or the SVPs, and are pivotal for HBV attachment to hepatocytes 
(Neurath et al., 1985). The S-domain occurring within LHBs is glycosylated 
(Stibbe and Gerlich, 1983) whilst, the PreS2-domain which is always glycosylated 
in MHBs is unglycosylated in LHBs proteins (Heermann et al., 1984). 
Myristylation and phosphorylation occur at the LHBs N-terminus, the myristate 
group is essential for infectivity but not replication (Persing, Varmus and Ganem, 
1987; Le Seyec et al., 1999).  Transmembrane insertion of LHBs molecules in the 
lipid bilayer is facilitated by the myristate group (Bruss and Ganem, 1991).             
 
 
1.3.3.1.2 MHBs (31 kDa) is coded for by nt 3206 – 835, generating a 2.1 kb 
mRNA transcript to synthesise a 281 aa protein (Heermann et al., 1984). MHBs is 
a N-glycosylated protein consisting of both PreS2 and S-domains. An O-glycan 
residue can be found at aa 37 and an acetyl-residue is found at the N-terminus 
(Heermann et al., 1984). The function of this molecule is not essential for any 
viral activity, such as infectivity (Fernholz et al., 1993), however some antigenic 
epitopes are located within the PreS2-domain (Neurath et al., 1985). The Spacer-
region of the polymerase molecule overlaps with the PreS2-region and large 
deletions or mutations in these regions are well tolerated (Fernholz et al., 1993; 
Pollicino et al., 2014).  
 
 
1.3.3.1.3 SHBs (or HBsAg) encoded by nt 155 - 835, produces a 226 aa molecule 
from the PreS/S ORF. Similar to MHBs, SHBs molecules are transcribed from the 
2.1kb mRNA transcript (Heermann et al., 1984). SHBs is the most abundant of 
the surface proteins constituting 80% of the envelope proteins (Robinson, 1977). 
Glycosylation of SHBs is essential for secretion of virions however not all SHBs 
are glycosylated. SHBs has a molecular weight of 24 kDa when unglycosylated 
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and 27 kDa when glycosylated. The role of SHBs in HBV-virion binding to 
hepatocytes is lesser than that of LHBs, however SHBs is required for 
transmission of infection (Glebe and Urban, 2007).  The ‘a’ determinant is found 
within the SHBs molecule, and is the most important HBV antigenic epitope, used 
to detect active HBV infection and is the target of neutralising anti-HBs, produced 
by the host (Honorati and Facchini, 1998; Nassal, 2008). 
 
 
SHBs has five transmembrane α-helices (Helix I to V) which contain both 
hydrophilic and hydrophobic regions (Tiollais and Wain-Hobson, 1984; Eble, 
Lingappa and Ganem, 1986). Each helix has 4 - 5 hydrophobic coils traversing the 
ER membrane, which becomes the virion membrane. Helix I, begins with the N-
terminus exposed to the cytoplasm, the helix then translocates the molecule across 
the ER membrane, terminating with the first major hydrophilic loop (49 aa), either 
in the cytoplasm of the host or later, the interior of the virion (Prange and Streeck, 
1995).  
 
 
Helix II contains an 18aa long (aa 80 - 98) hydrophobic domain, this helical 
structure transverses the ER membrane terminating in the lumen of the ER (or 
Golgi Apparatus (Golgi)), the second major hydrophilic structure of SHBs 
extends from Helix II  (Eble, Lingappa and Ganem, 1986). It is within this 
hydrophilic region that the ‘a’ determinant is found. This is a cysteine-rich region, 
resulting in the formation of disulphide bonds between complimentary amino 
acids, allowing the molecule to form a loop (Mangold and Streeck, 1993). The ‘a’ 
determinant is found between amino-acids 99 and 168 of the SHBs and is 
considered the hallmark epitope of HBV. Mutations in this region can result in 
detection escape or immune/vaccine escape mutants (Weinberger et al., 2000).  
The ‘a’ determinant is common to all serological subtypes and is characterised by 
a threonine or isoleucine at position 126 (Kramvis and Kew, 2005), due to the 
conserved nature of ‘a’ determinant they are used in HBV vaccines conferring 
protection to all sub-types. 
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The ‘a’determinant is used to distinguish between the ten serological sub-types 
based on the allelic variations of the ‘a’ determinant (Tiollais and Wain-Hobson, 
1984). Amino-acids 122 and 160 of SHBs are used to differentiate between 
serotypes d/y and/or w/r respectively. At position 122 a lysine or an arginine can 
be found for serotype ‘d’ or ‘y’, respectively. Position 160 is characterised by a 
lysine or arginine, when distinguishing between serological subtypes ‘w’ or ‘r’, 
respectively. Recent studies found that positions 134, 140 and 159 are important 
for w1 subtypes and position 127 for w2-w4. Additionally amino acid 177 is used 
to distinguish between adrq+ and adrq- whilst position 178 is used to distinguish 
adw4q+ and adw4q-(Okamoto et al., 1988; Locarnini, 2003; Kramvis, Kew and 
François, 2005; Purdy et al., 2007). Helices III, IV and V also traverse the ER 
membrane, notably the order in which the five helices are arranged differs 
between LHBs, MHBs and SHBs (Locarnini, McMillan and Bartholomeusz, 
2003).  
 
 
1.3.3.2 HBV Polymerase  
The Pol gene is located between nt 2307 – 1623, this 90 kDa protein is 
synthesised from the 3.4 kb pgRNA. The N-terminus of this 845aa protein is 
bound to the 5’-end of the minus-strand. HBV polymerase is comprised of four 
domains: the terminal protein, spacer, RNA- and DNA-dependent reverse 
transcriptase, and RNase H (Seeger and Mason, 2000).  
 
 
Terminal protein (1 - 183 aa) is used in minus-strand priming (Stuyver et al., 
2001). The function of the spacer domain is yet to be elucidated, however large 
deletions in this domain do not inhibit polymerase function(Beck and Nassal, 
2007). The third Pol domain is responsible for reverse transcriptase/polymerase 
activity whereby the minus-strand is synthesized from the pgRNA template 
(Nassal, 2008). Synthesis of the plus-strand using the minus-strand as a template 
is enabled by the reverse transcriptase. The aa sequence YMDD, responsible for 
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reverse transcriptase activity, is found in the reverse transcriptase 
domain(Schlicht, Bartenschlager and Schaller, 1991). Lastly the RNAseH domain 
degrades the pgRNA template during minus-strand synthesis. The polymerase 
protein is vital in the treatment of HBV infection, as this is a protein targeted by 
most therapies  (Rehermann et al., 1995). The polymerase contains two T-cell 
epitopes between aa 107 – 115 and 227 – 235 (Locarnini, 2003). 
 
 
1.3.3.3 HBc  
The core gene is located between nt 1901 and 2450, translating the 3.4 kb pgRNA 
into a 183 aa HBc (183-195 aa in length depending on genotype) with a molecular 
weight of 21 kDa (Tiollais, Pourcel and Dejean, 1985; Will et al., 1987). The first 
functional domain involving aa 1 -144 of HBc (the assembly domain), is involved 
in encapsidation and replication (Ganem and Schneider, 2001). The second 
domain (nucleic-binding domain) of approximately 43 aa (aa 145 - 187) includes 
the arginine-, serine- and proline-rich C-terminus, involved in anchoring HBV-
DNA to the nucleocapsid. During nucleocapsid formation, the core protein 
monomers dimerise, using disulphide bonding. The dimers spontaneously form an 
icosahedral structure of 36 nm consisting of 120 dimers or a smaller structure 
composed of 90 dimers. These icosahedral structures encapsidate the HBV 
genome, therefore referred to as nucleocapsids (Seeger and Mason, 2000). The 
core protein contains four alpha-helices and two exposed regions, the first of these 
regions is a protrusion at the dimer-binding sites and the other is involved in the 
assembly of the dimers into the multimer structure (Seeger and Mason, 2000). 
 
 
1.3.3.4 HBe 
Translation of the core gene from the upstream PreCore (nt 1814 - 1900) region 
results in the production of a non-particulate, soluble protein, HBe (Nassal, 
Junker-Niepmann and Schaller, 1990). Translation of the second species of 3.5 kb 
mRNA, the PreC/Core mRNA transcript, produces a HBe precursor protein of 
210 aa, p25. The first 19 aa of HBe (p25) contain a signal peptide that directs the 
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protein to the ER where these 19 aa’s are cleaved off by cellular signal peptidase, 
resulting in another protein intermediate (p22) that is subsequently translocated 
into the Golgi for further post-translational modification. After approximately 34 
aa are cleaved off the C-terminus, the final derivatives are 15 – 18 kDa 
heterogenous species of HBe, (Tiollais, Pourcel and Dejean, 1985) of which most 
is secreted into serum whereas 20% is retained in the cytoplasm. A small amount 
of HBe precursor (p25) remains in the cytoplasm, furthermore this precursor 
contains nuclear signalling properties transporting it back into the nucleus, 
therefore HBe and its precursors can be found in almost all cellular compartments 
(Ganem and Varmus, 1987). HBe is not required for replication and its function 
remains enigmatic, however it is a highly conserved region, which is postulated to 
have immune tolerant functions (Milich et al., 1990; Miyakawa, Okamoto and 
Mayumi, 1997). HBV does require HBe to establish persistent infection but not to 
sustain infection high levels of HBe have been associated with high HBV viral-
loads but normal liver histology and viral replication. Lower levels of HBe have 
been associated with more rigorous host immune activity against HBV, alluding 
to the immune-tolerogenic function of HBe. The TLR signalling pathway is 
antagonised by HBe retained in the cytoplasm further impairing immune function 
(Lang et al., 2011). 
 
 
1.3.3.5 HBx  
The x-gene is located between nt 1374-1836, coding for the 17kDa x-protein 
(HBx), using the x-mRNA transcript (Tiollais, Pourcel and Dejean, 1985). 
Although this 154 aa protein is essential for infectivity, the role played in this 
process is unknown. HBx is a transactivator of numerous cellular and viral gene 
promoters namely; RBP5 (a sub-unit of RNA Polymerase II), TATA-binding 
protein. Various signal transduction pathways such as Ras/Raf/MAP kinase 
cascade, AP-1 and NF-кB, are also activated by the HBx (Locarnini, McMillan 
and Bartholomeusz, 2003). HBx binds to and inhibits the tumor suppressor 
protein p53 implicating a role in HBV associated HCC.  
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1.3.4 HBV Life Cycle 
1.3.4.1 Attachment and Entry Into Hepatocytes  
The first step in the life-cycle is specific attachment to the sodium taurocholate 
receptor found on thehepatocyte surface (Yan et al., 2014), facilitated by the 
PreS1 domain of LHBs (Urban, 2008). Entry into the cytoplasm occurs either by 
receptor-mediated endocytosis or cell-membrane fusion. Microtubules are used to 
transport the nucleocapsid through the cytoplasm to the nuclear-pore (Kann, 
Schmitz and Rabe, 2007). Prior to the release of HBV rcDNA into the 
nucleoplasm, the nucleocapsid is disassembled on the cytoplasmic side of the 
nuclear-pore (Tuttleman, Pourcel and Summers, 1986).  
 
1.3.4.2 cccDNA Formation 
Covalently closed circular (ccc)-DNA formation of HBV-DNA from partially ds-
rcDNA is essential for HBV replication. The following events need to occur to 
allow cccDNA formation, removal of the polymerase from the minus-strand, 
removal of the 18 nt RNA oligomer at the 5’-end of the plus-strand, the 
incomplete plus-strand is repaired using host-cell enzymes (such as cellular DNA 
polymerase) and the plus- and minus-strands become covalently bound (Bock et 
al., 2001). Using, cccDNA as a transcriptional template, host-derived RNA 
polymerase II, along with liver-specific enzymes and non-specific transcription 
factors, the four HBV mRNAs are transcribed (Sommer, van Bömmel and Will, 
2000). The 3.5 kb overlength pgRNA is used not only to transcribe the core and 
polymerase proteins, but serves as the template for viral replication later on. 
 
Histological analysis of HBV infected hepatocytes, displays episomal structures, 
which are mini-chromosomes formed by cccDNA using histones (Bock et al., 
2001). A single hepatocyte can contain 50 or more copies of cccDNA (Zhu et al., 
2001). The half-life of DHBV cccDNA is 30 – 60 days (HBV is assumed to have 
a similar half-life) (Beck and Nassal, 2007), which is believed to be longer than 
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hepatocyte cellular regeneration therefore cccDNA persists in newly synthesized 
hepatocytes (Zhu et al., 2001). cccDNA is responsible for persistence of chronic 
HBV infection (Levrero et al., 2009).      
 
1.3.4.3 Formation of Nucleocapsids 
The mRNA transcripts generated in the nucleus are delivered to the cytoplasm for 
translation (Hirsch et al., 1990). The newly synthesized core protein molecules 
dimerise thereafter, using host-chaperone molecules the dimer sub-units 
spontaneously assemble, forming nucleocapsids each containing a single copy of 
pgRNA attached to a polymerase molecule (Hirsch et al., 1991; Wynne, Crowther 
and Leslie, 1999).  
 
1.3.4.4 Reverse Transcription 
HBV is sometimes referred to as a para-retrovirus because it reverse transcribes 
DNA from an RNA template (Summers, 1987). Within the nucleocapsids, the 
HBV polymerase binds to a stem-loop structure, the epsilon or encapsidation 
signal (ε) (Junker-Niepmann, Bartenschlager and Schaller, 1990). The 5’-UUC-3’ 
motif on ε is used to transcribe the first aa (tyrosine) of the minus-strand. The 
tyrosine molecule is used to prime the pgRNA to initiate reverse transcription and 
synthesis of the minus-strand (Wang and Seeger, 1993). The Pol-tyrosine complex 
translocates to DR1 at the 3’-end of the pgRNA, for elongation of the minus-
strand (Rothnie, Chapdelaine and Hohn, 1994). During minus-strand synthesis, 
RNAse H degrades the pgRNA, with the exception of an 18 nt oligomer 
(including DR1) at the C-terminus of the pgRNA, which remains bound to the 3’-
end of the minus-strand (Loeb, Hirsch and Ganem, 1991).  
 
The RNA-oligomer translocates to DR2 whereby it primes plus-strand synthesis. 
The plus-strand remains incomplete, ceasing synthesis after 50 - 70% of 
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complementing the minus-strand (Beck and Nassal, 2007). The elongated plus-
strand transfers to the 3’-end of the minus-strand. Base-pairing between the plus- 
and minus-strands results in the formation of partially double-stranded rcDNA. 
Post reverse-transcription the ds-rcDNA either returns to the nucleus for another 
round of replication or matures into a Dane particle (Nassal and Rieger, 1996). 
 
1.3.4.5 Maturation of HBV Virion 
The nucleocapsid, containing a single copy of rcDNA, enters the ER 
(Bartenschlager and Schaller, 1992), following which, it attaches to the PreS1 
domain of LHBs inserted in the ER membrane (Bruss et al., 1994). During 
budding-off from the ER the nucleocapsid becomes enveloped with the ER 
membrane containing HBV surface proteins and host-derived lipids, releasing 
mature virions into the Golgi, where they are encapsulated in multi-vesicular 
bodies in preparation for exocytosis (Demirov and Freed, 2004). Following 
exocytosis the virions either enter the host’s circulation or infect neighbouring 
hepatocytes (Gerelsaikhan, Tavis and Bruss, 1996).   
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Figure 1.5 HBV Replication Cycle: The process begins with attachment 
followed by endocytosis, subsequently envelope removal, thereafter releasing the 
nucleocapsid into the cytoplasm. Microtubules deliver the nucleocapsid to the 
nuclear-pore, for uncoating and release of rcDNA into the nucleoplasm. cccDNA 
formation and the production of mRNAs occurs within the nucleus. These are 
used to synthesize HBV structural and non-structural proteins in the cytoplasm. 
The proteins produced, are used in reverse-transcription and virion formation. 
Nucleocapsids are assembled thereafter allowing reverse transcription to occur 
within the capsid. Nucleocapsids are then transported back to the nucleus for 
another replication cycle or are delivered to the ER for encapsidation. The 
enveloped virions  thereafter enter the Golgi preparing it for exocytosis(Gerlich, 
2013). Reproduced in accordance with the Open Data Policy of Biomed Central 
and the Creative Commons CC1.0 Public Domain Dedication Waiver 
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1.3.5 HBV Genotypes and Serological Subtypes 
1.3.5.1 Genotypes  
Genotypes refer to the genomic constitution of an organism, moreover it can be 
described as the replication competent sequence variant that has stabilized after a 
prolonged period of time (Kramvis, Kew and François, 2005). HBV is classified 
into genotypes and subgenotypes. Many studies have demonstrated genotype or 
subgenotype specific geographic distributions, mutation selection, clinical 
manifestations, transmission routes, response to anti-retroviral therapy and 
progression to severe liver disease(Kramvis and Kew 2007; Pujol et al., 2009). 
Therefore understanding the differences among the genotypes and subgenotypes 
is advantageous. Genotypes are variable in genome length, ORF length and 
mutations (Kramvis, Kew and François, 2005). There are 9 genotypes of HBV (A-
I) and a putative tenth, genotype ‘J’, this based on an intergroup nucleotide 
divergence of >8% (Okamoto et al., 1988; Norder, Courouce and Magnius, 1992; 
Kramvis, Kew and François, 2005; Yu et al., 2010). Genotypes are further 
stratified into subgenotypes based on a nucleotide divergence of 4-8% (Miyakawa 
and Mizokami, 2003; Tatematsu et al., 2009; Kramvis, 2014).   
 
 
1.3.5.2 Serological Subtypes 
Previously serological-typing was used to distinguish between the various strains 
of HBV, based on the ‘a’ determinant in SHBs (Norder, Courouce and Magnius, 
1992). However genotyping is more widely used, due to the limitations of 
serological subtyping (Kao & Chen 2006). The ‘a’ determinant is used to 
distinguish between ten serological sub-types based on the allelic variations of 
this region (Tiollais and Wain-Hobson, 1984). Amino-acids 122 and 160 of SHBs 
are used to differentiate between serotypes d/y and w/r, respectively. At position 
122 a lysine or an arginine can be found for serotype‘d’ or ‘y’, respectively. 
Position 160 is characterised by a lysine or arginine, when distinguishing between 
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serological subtypes ‘w’ or ‘r’, respectively. Recent studies have found that 
positions 134, 140 and 159 are useful in describing subtypes w1 and position 127 
for w2-w4. Additionally nt 177 is used to distinguish between adrq+ and adrq- 
whilst position 178 is used to distinguish adw4q+ and adw4q-(Okamoto et al., 
1988; Locarnini, 2003; Kramvis, Kew and François, 2005; Purdy et al., 2007). A 
correlation between genotyping and serotyping exists, with adw associated with 
genotypes A, B, F, G and H and ayw associated with genotypes D and E however, 
this is not a rule (Kramvis et al., 2008). 
 
 
1.3.5.3 Geographic Distribution of Genotypes 
Genotype A is widespread across Africa, subgenotype A1 is found predominantly 
in Africa, specifically sub-Saharan Africa , and Asia (Bowyer et al., 1997; Kimbi, 
Kramvis and Kew, 2004; Kramvis and Paraskevis, 2013). Subgenotype A3 and 
A4 are found in Africa and Haiti, with subgenotype A2 found in Europe and 
North America (Hannoun et al., 2005; Kurbanov et al., 2005). Subgenotypes B1 – 
B4 predominate in Asian countries with the exception of subgenotype B4, also 
found in France (Shi et al., 2012; Kramvis, 2014). Subgenotype B5 prevails in 
Eskimos and Inuits (Osiowy et al., 2006).  
 
Genotype C is the most sub-classified group of the HBV genotypes, having 16 
subgenotypes, found mostly in Asia (Shiet al., 2012). Subgenotype C3 however, 
circulates in New Caledonia and Polynesia whilst subgenotype C4 is predominant 
in Australian Aborigines  (Kato et al., 2003; Shiet al., 2012; Davies et al., 2013). 
The majority of genotype C subgenotypes occur in the Indonesian and Phillippino 
populations (Huy et al., 2004; Tanaka et al., 2006; Kramvis et al., 2008). Until 
recently this genotype was subdivided into 8 subgenotypes, when the work of 
Yousif and Kramvis 2013, provided a new classification method, whereby 
Genotype D was divided into six rather than eight genotypes. Genotype D is the 
most widely distributed genotype (Pujol et al., 2009). Subgenotype D1 is found in 
the Middle East and Central Asia whilst D2 is found in Europe, the Mediterranean 
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area, Japan and Lebanon (Norder et al., 2004; Schaefer, 2007). HBV subgenotype 
D3 is a globally distributed strain (Kramvis, 2014).Subgenotype D4 is found in a 
variety of populations namely Australian aborigines, Northern and Central 
Americas, Micronesians, Papua New Guineans and Arctic Denes (Norder et al., 
2004; Pujol et al., 2009). Subgenotype D5 is exists predominantly on the Indian 
subcontinent (Banerjee et al., 2006; Yousif and Kramvis, 2013), whilst Tunisia 
and Nigeria have the highest number of subgenotype D6 circulating in their 
respective countries (Kramvis and Kew 2007; Norder et al. 2004). 
 
Genotype E is found in mainly in western and central Africa (Kramvis et al., 
2005) .  With only four subgenotypes, genotype F prevails in central and South 
America, with the exception of subgenotype F1, which is also found in Alaska 
(Huy et al., 2004; Kato et al., 2005). With a wide geographic distribution, 
genotype G prevails in North America, Mexico, Germany, Italy, France and the 
UK (Tanaka et al., 2004; Lindh, 2005). Genotype H is predominant in Mexico, 
Japan, Nicaragua and the USA (Arauz-Ruiz et al., 2002) Genotype I has only two 
subgenotypes distributed in Laos, Vietnam, China and India (Yu et al., 2010). The 
putative tenth genotype, “J”, exists only in Japan (Tatematsu et al., 2009).  
Currently no subgenotypes have been reported for genotypes E, G, H or J.  
 
 
1.3.5.4 Genotypes Prevalent in sub-Saharan Africa 
Subgenotype A1 is the dominant strain of HBV in sub-Saharan Africa (Kramvis, 
Kew and François, 2005). Subgenotypes A1 and A2 are found in sub-Saharan 
Africa, whilst subgenotypes A3 and A4 are predominant in central and west 
Africa (Pujol et al., 2009).   Genotype E prevails in western Africa, with genotype 
D found globally (Norder et al., 2004; Schaefer, 2007; Pujol et al., 2009; Yousif 
and Kramvis, 2013). 
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Even within subgenotype A1 there are variations depending on the geographical 
location.   The African subgenotype A1 clade has a greater nucleotide divergence 
than the Asian clade therefore Africa is the probable origin of this subgenotype 
(Kramvis and Kew, 2007). This is supported by evidence of historical migration 
patterns indicating that subgenotype A1, may have spread to the Indian 
subcontinent and South America, from Africa during the slave trade  (Kramvis 
and Paraskevis 2013; Alvarado-Mora et al., 2013). Subgenotype A2 is found 
predominantly in Europe, but is believed to originate in southern Africa hence it 
can still be found in this region. European travellers to sub-Saharan Africa in the 
fifteenth century are supposedly responsible for introducing this strain into the 
European population (Hannoun et al., 2005). Subgenotype A2 differs from 
subgenotype A1 in various regions of all HBV genes, resulting in different protein 
characteristic between these subgenotypes (Kimbi, Kramvis and Kew, 2004). 
      
 
Figure 1.6 Global distribution of HBV genotypes Reprinted from Infections, 
Genetics and Evolution with permission from Elsevier (Shi et al., 2013) 
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1.3.5.5 Genetic variations among genotypes 
Genotype A contains six additional nucleotides at the carboxyl-end of the core 
gene and is characterised by an ‘A’ at position 1888. Genotype D has a 33 
nucleotide deletion in the PreS1 region at the amino-terminus (Kramvis, 2014). 
Characteristic to Genotype E is a three nucleotide deletion at the amino terminus 
of the PreS1 region. A 36 nucleotide insert at 3’ - end of nt 1905, a three 
nucleotide deletion at the amino terminus of the PreS1 region and two stop codons 
at amino-acids 2 and 28 of the PreC region, are distinct characteristics of 
Genotype G. Genotype J has a 33 nucleotide deletion at the N-terminus of the 
PreS1 region (Norder, Couroucé and Magnius, 1994; Stuyver et al., 2000; 
Kramvis, Kew and François, 2005; Purdy et al., 2007).    
 
Genotypes B, C, F, H and I have genomes of 3215bp whilst, genotypes D and J 
are both characterised by genome lengths of 3182bp. Genotypes A, E and G have 
genome lengths of 3221bp, 3212bp and 3248bp, respectively. Genotypes A, D 
and E are characterised by a ‘CG’ at loci 1802-1803 however genotypes B, C and 
F have a ‘TT’ at the same positions. Loci 1858 is associated with a, ‘C’ in 
genotypes A, F and H, and a ‘T’ with genotypes B, D and E (Stuyver et al., 2000; 
Purdy et al., 2007; Kramvis et al., 2008). These distinctions allow easier 
identification of genotypes and infer information about protein expression and 
functional differences resulting from the respective insertions or deletions. 
 
Recombination of genotypes has been documented, occurring most frequently in 
the BCP/PreC, small S and core regions (Simmonds and Midgley, 2005; Shi et al., 
2013). Recombinants of genotype D/E have been reported in Africa. 
Subgenotypes B1 and B5 do not contain recombinant sequences of genotype C in 
the PreC/C region, as do the rest of the B subgenotypes (Sugauchi et al., 2002; 
Kramvis, 2014). Aside from recombination, in areas where two or more genotypes 
coexist, co-infection with different genotypes have been reported (Kramvis, Kew 
and François, 2005).   
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1.3.5.6 Clinical differences between genotypes found in Sub-Saharan African  
The heterogeneity of HBV subgenotypes contributes to pathogenic and/or 
therapeutic differences (Kramvis and Kew, 2005; Kao and Chen, 2006). Persons 
infected with subgenotype A1 demonstrate an increased risk of HCC, than those 
infected with other non-A genotypes (Kew et al., 2005). Subgenotype A1 
infections are associated with increased HBeAg-negativity in all individuals and 
high HBsAg-negativity in HBV-HIV co-infected individuals (Kramvis and Kew, 
2007; Mphahlele et al., 2006). Additional associations with subgenotype A1 are, 
low HBV DNA levels and higher rate of HBeAg-negativity compared to 
subgenotype A2. Subgenotype A2 has a lower risk of developing serious disease 
sequelae and clears HBeAg later than subgenotype A1 (Tanaka et al., 2004). In 
comparison to other genotypes in sub-Saharan Africa, subgenotype A1 infected 
individuals have a risk of developing HCC, and the onset thereof occurs at a 
younger age (Kew et al., 2005). 
 
In studies carried out on other continents, where subgenotypes differ from those 
prevailing in Africa, genotype D is associated with greater risk of HCC 
development and severity of disease than genotype A (Thakur et al., 2002; Pujol 
et al., 2009). An Indian study reported early HBeAg seroconversion, as a result of 
the aggressive nature of Genotype D infections. This early seroconversion could 
result in an earlier onset of HCC compared to Genotype A (Thakur et al., 2002). 
Although there are exceptions(Gopalakrishnan et al., 2013) subgenotype A2 is the 
predominant subgenotype of A prevailing in India.  Genotype D does not respond 
as efficiently to anti-viral treatment, compared to genotype A (Lin and Kao, 
2010), supposedly caused by the high number of anti-viral resistance mutations 
associated with Genotype D (Schaefer, 2007). Genotype E has higher viral-loads 
and a higher frequency of HBeAg positivity than Genotype D (Cote et al., 2000; 
Yousif et al., 2013).  
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1.4. Natural history 
The dynamic natural history of HBV begins with an asymptomatic or 
symptomatic acute phase, lasting 6 months or less. The chronic phase of infection 
is characterized by varying degrees of severity ranging from an inactive carrier 
state to liver necro-inflammation progressing to liver cirrhosis, End Stage Liver 
Disease (ESLD) and HCC. Hepatitis B infections are detected by abnormal liver 
histology, fluctuating levels of liver transaminases, HBsAg detection and the 
presence of HBV-DNA in serum (McMahon, 2004; Lok and McMahon, 2009). 
From a virologic perspective there are replicative and non-replicative phases, 
during the natural history of HBV infection (Fattovich, 2003).  
 
1.4.1 Acute Hepatitis  
Following infection the virus undergoes an incubation period lasting between 1-6 
month/s (Ganem and Prince 2004). In subclinical acute infections HBeAg and 
HBsAg are serologically detectable two weeks post-infection, remaining present 
up to 8 weeks thereafter. Anti-HBc is present early during infection, whilst anti-
HBs is detectable as HBV replication decreases. One-third of acutely infected 
individuals become symptomatic, initially presenting with: fever; fatigue; 
anorexia; nausea; jaundice; dark urine; clay or pale-coloured stools and general 
malaise. Symptomatic acute infections are characterised by HBsAg-positivity, 
detectable HBV-DNA in serum, elevated ALT and AST levels, liver inflammation 
and hepatocellular necrosis (Liang, 2009). Acute hepatitis B is self-limiting, 
resolving after 3-6 months (WHO, 2015). The case fatality rate in acute infections 
is 0.5-1% (Lavanchy, 2004). Although fulminant hepatic failure is possible it is 
rare, occurring in 1-2% of acute infections (Sulkowski, 2008), resulting in severe 
symptoms such as fever, abdominal pain, vomiting, jaundice and disorientation 
including symptoms of acute infection (Berk and Popper, 1978). 
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HBsAg positivity for longer than 6 months is considered indicative of progression 
to chronic HBV infection (CHB), the same applies to increased ALT levels longer 
than 6 months (Hoofnagle, 1981; Ribeiro, Lo and Perelson, 2002), only 5% of 
acute infections become chronic if an individual is infected in adulthood 
(Mahoney, 1999).           
 
1.4.2 Chronic Hepatitis 
Most patients are asymptomatic and infection may remain undiagnosed until liver 
disease has progressed.  Chronicity and the severity thereof is dependent on the 
age at which infection occurred, as well as the route of transmission (Sugiyama et 
al., 2006). Chronic infection is most prevalent in neonates occurring in 90% of 
those infected perinatally, in children under the age of five years 20-60% develop 
chronic infection whilst in adults approximately 5% develop chronic infection 
(McMahon, 2004; Hoofnagle et al., 2007).  
 
CHB is dynamic, with four phases of infection and variable degrees of sequelae, 
these phases do not always occur sequentially or do not strictly adhere to their 
respective characteristics (Bertoletti and Kennedy, 2015). Four phases of infection 
characterised by host-immune and virological responses these are: high 
replicative, low inflammatory phase, immune clearance phase, HBeAg-negative 
chronic hepatitis phase and the low replicative phase.  
 High replicative, low inflammatory phase 
This asymptomatic phase is characterised by HBeAg and HBsAg positivity, 
high HBV viral-loads (>2 x 105 IU/ml), normal or slightly elevated ALT and 
aspartate amino transferase (AST) (Chang et al., 1988; Takashima et al., 
1992) . The duration of this phase is between 10-30 years occurring most 
frequently in those infected perinatally or during early childhood these 
individuals generally are HBsAg-positive. Individuals infected in adulthood 
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do not typically experience this phase (Shi et al., 2009). Disease progression 
to fibrosis or HCC is minimal, during this phas 
e (Hui et al., 2007).         
 
 Immune clearance phase 
This immune active phase is initially characterised by fluctuating ALT and 
HBV DNA levels followed by HBeAg seroconversion, elevated ALT levels, 
decreased levels of HBV-DNA and signs of hepatic-inflammation resulting in 
abnormal liver histology. The neutralizing anti-HBc assist in containing 
infection by preventing infection of uninfected hepatocytes (Gerlich, 2013).  
This phase lasts a few weeks up to several years, occurring in the second or 
third decade of life in those infected perinatally or during early childhood 
(Shi, Shi and Al, 2009). Liver damage begins during the immune clearance 
phase, due to necroinflammation, especially if an individual experiences this 
phase for a prolonged period. Some clinical symptoms may start to present 
during immune clearance (Fattovich, 2003; Ganem and Prince, 2004).    
 
 HBeAg-negative chronic hepatitis  
Necroinflammation persists during this phase with high or fluctuating ALT 
levels. HBV DNA levels are high to moderate whilst liver disease is 
progressive (Gish et al., 2015) 
 
 Low replicative phase 
This is the low or non-replicative phase of HBV infection showing marked 
decrease in HBV viremia, sometimes to undetectable levels. HBeAg 
seroconversion to anti-HBe occurs during this phase, indicative of infection 
remittance. ALT levels normalise whilst inflammation and fibrosis decrease 
(Hoofnagle et al., 2007). If severe sequelae of liver disease did not occur by 
this phase the individual has a good prognosis, whilst the risk of severe liver 
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disease such as cirrhosis and HCC are drastically reduced. Most chronic 
carriers of HBV are found to be in this inactive carrier phase. Only 0.5% of 
inactive carriers clear HBV, annually (Seto et al., 2014). 
 
A  reactivation phase has been described which occurs when the immune system 
becomes compromised for example in HIV-infected patients or those undergoing 
chemotherapy (WHO, 2015). Individuals who have resolved the infection and are 
both HBsAg and HBV-DNA negative but anti-HBc positive, may experience 
reactivation under severe immune-compromise (WHO, 2015).This phase is 
characterised by anti-HBc positivity, fluctuating HBV-DNA and ALT levels and 
an increased risk of progression to severe hepatic fibrosis (Fattovich, 2003). 
Reactivation of infection may lead to fatal acute-on-chronic hepatitis. CHB 
suffers need to be regularly monitored as fluctuations in HBV-DNA and ALT-
levels make diagnosis and staging difficult (Shi, Shi and Al, 2009). HBsAg 
positivity is maintained throughout chronic infection.  However in occult HBV 
infection (OBI) the HBsAg is not detectable in serum but HBV DNA can be 
found in the liver (Raimondo et al., 2008).  
 
1.4.3 Long-term effects of CHB 
CHB long-term sequelae range from hepatic-fibrosis, decompensated cirrhosis, 
ESLD to HCC. These outocmes are determined by viral, host and environmental 
factors. In those adults who contracted HBV during childhood or infancy 15-25% 
are at risk of fatal liver disease during adulthood (Wong and Wong, 2013). Adults 
with high HBV DNA levels (> 2000 IU/mL), experience higher rates of cirrhosis 
and HCC (Chen et al., 2006). Approximately one-third of CHB sufferers will 
develop long term sequelae. HBsAg seroclearance is not common in chronic 
infections.  When HbsAg loss occurs prognosis is improved although the infection 
is never eliminated completely (Terrault et al., 2015).    
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It is well established that HBV-infection leads to fatal liver-cirrhosis or HCC. 
HCC is not always preceded by cirrhosis (Neuveut, Wei and Buendia, 2010).  
HCC usually develops as a result of mutations or clonal insertions of truncated or 
rearranged HBV-DNA. Oncogenes such as myc may be activated by HBV 
enhancers and promoters (Liu et al., 2009). HBV-DNA levels, HBeAg sero-status 
and cirrhosis are important predictors in the development of HCC.   
 
Chronic hepatitis leads to cirrhosis in 10-20% of cases, compensated cirrhosis 
progresses to hepatic decompensation and HCC in 30%  and 15 % of CHB cases, 
respectively, within a five year period (Fattovich, Bortolotti and Donato, 2008). 
HBV-DNA levels, ALT levels and HBeAg sero-status are the most important 
determinants in progression to cirrhosis (Chen et al., 2006).  
 
1.5 Serology  
1.5.1 HBsAg and Anti-HBs 
HBsAg is used as an indicator of infection it is also the first serological marker to 
appear in serum, appearing 1-10 weeks after infection. HBsAg is considered an 
indication of transcriptional activity of HBV cccDNA (Lok and McMahon, 2009). 
Anti-HBs appears in individuals who are immune by vaccination against HBV or 
have recovered from a previous infection. Post-vaccination anti-HBs is detectable 
in serum. In some areas HBV surface antigen (HBsAg) sero-status is used as the 
sole indicator of active HBV infection (Krajden, McNabb and Petric, 2005). 
Persistence of HBsAg-positivity is the principal serological marker of liver-
disease risk profiling. HBsAg-negativity seen in OBI infected individuals can 
either be the result of low HBV viral loads, the formation of immune-complexes 
or mutations in the region coding for the HBsAg, which can change the 
immunogenicity of the protein, thus infection is undetected by serological assays 
i.e. detection escape mutations (Torresi, 2002).  
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1.5.2 HBeAg, Anti-HBe, HBcAg and Anti-HBc 
HBeAg reflects replication of HBV, sero-conversion to anti-HBe, is indicative of 
HBV replication cessation, which presents at the end of immune clearance phase. 
Anti-HBc can be either IgG or IgM and are collectively referred to as anti-HBc. 
IgG can be used to determine previous exposure to HBV even in the absence of 
anti-HBs whilst anti-HBc IgM appears during acute infection or reactivation. IgM 
appears during HBsAg seroconversion to anti-HBs (Keeffe et al., 2004; Lok and 
McMahon, 2009). 
 
An individual is considered to be acutely infected with HBV, if the person is 
serologically positive for both HBsAg and anti-HBc IgM (Krajden, McNabb and 
Petric, 2005). Previous studies from sub-Saharan Africa found, individuals test 
sero-positive for HBV surface antibody (anti-HBs) ‘alone’ (which is indicative of 
having resolved a HBV-infection) but are HBV-DNA positive (Owiredu, Kramvis 
and Kew, 2001; Mphahlele et al., 2006).  
 
1.6 HBV-HIV co-infection  
Two thirds of the 34 million HIV-infections in the world, reside in sub-Saharan 
Africa, which is also high endemicity (15%) region of HBV (Matthews et al., 
2014). HBV and HIV share transmission routes (parenteral, vertical and sexual) 
therefore chronic co-infection with these viruses is frequent occurring in 5-10% of 
HIV-positive individuals. Barth et al., 2010 found that 15% of HIV-infected 
individuals in sub-Saharan Africa are chronic carriers of HBV. Prevalence of 
CHB in co-infected individuals is ten times higher than in HIV-mono-infected 
individuals (Spradling et al., 2010). Given that sub-Saharan Africa has an 
estimated 2.5 million persons chronically infected with HBV (McMahon, 2004; 
Puoti et al., 2006), there is an increased risk of chronicity and OBI in HBV-HIV 
co-infected persons versus mono-infected (Spearman et al., 2013). There is a 
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more rapid progression to cirrhosis, ESLD or HCC in HIV-infected CHB sufferers 
(Cardona et al., 2011). 
 
Five percent of HIV-positive sub-Saharan African adults (15 years and older) are 
burdened with HBV-HIV co-infection (World Health Organisation, 2016). Only 
one third of HBV infections are detected in HIV-positive individuals, in a routine 
clinical laboratory setting, leaving a large majority of HBV-HIV co-infected 
patients undiagnosed and untreated (Bell et al., 2012). Infection with HBV is not 
always considered in the management of HIV-infection, although co-infection has 
been associated with an increased turnover rate of liver morbidity, and 
complicated HIV pathology (Ayuk, Mphahlele and Bessong, 2013). Whilst 
increasing the life-expectancy of HIV-positive individuals with Anti Retrovirals 
(ARV), failure to manage HBV-infection leads to liver disease and HCC in co-
infected individuals. HIV-infection results in an earlier onset of HCC (Soriano et 
al,. 2008; Puoti et al. 2004). Co-infection increases progression to cirrhosis and 
the risk to HCC (Hoffmann and Thio, 2007; Sulkowski, 2008). 
 
The World Gastroenterology Organisation (WGO) explains that a principle 
objective in the suppression of HBV-induced liver disease in HIV-positive 
individuals, is to delay or prevent hepatic-cirrhosis or HCC (WGO, 2015). 
Additionally, ARV use should be maintained as long-term therapy for sustained 
viral suppression. HBV-HIV co-infected individuals should strive to sustain 
normal ALT levels, suppress HBV viral replication and show histologic 
improvement to prevent liver-disease. Immune reconstitution after ART can cause 
exacerbations of HBV infection when the immune clearance phase begins, as the 
immune system mounts a rigorous attack on the liver resulting in severe 
consequences. Despite the great risk associated with the development of 
resistance to the ARV’s used in treatment of co-infected individuals, there is 
greater risk involved in a lack of therapy, possibly resulting in fatal liver disease. 
Therefore combination therapy is required in such individuals.     
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1.7 Study Background 
The baseline studies by Bell et al., 2012and Makondo, Bell and Kramvis, 
2012determined the HBV genotypes and subgenotypes of the study population  
and identified mutations in the BCP/PreC and complete S region mutations. Of 
the 298 Lam-treatment naïve, HIV-infected adults enrolled into the study, 71 had 
detectable HBV DNA. The number of lifetime sexual partners was the 
significantly higher in the participants with detectable HBV DNA compared to 
those that were HBV DNA negative(Bell et al., 2012). Subgenotype A1 was the 
predominant strain found in this study with numerous mutations in the BCP/PreC 
region that could account for the high prevalence of HBeAg negative infection 
associated with this subgenotype. The G1862T mutation located in the BCP/PreC 
region was significantly associated with HBsAg positive HBV infection (p< 0.05). 
Deletions and mutations were found on the S region, explaining the HBsAg 
negativity occurring in this cohort. Three isolates had drug resistance mutations 
rtV173L, rtL180M, rtM204V and rtV214A at baseline. Thirty-nine participants 
from the baseline study returned for follow-up, the present study compared the 
follow-up findings to that of the baseline studies to determine the effect of Lam on 
HBV infection. 
 
1.8 Rationale and Aims 
Whilst increasing the life-expectancy of HIV-positive individuals with ARV’s, 
conversely the situation is exacerbated with regards to liver disease and HCC. 
Given that only one third of HBV infections are actually detected in HIV-positive 
patients, in a routine clinical laboratory setting this leaves a large majority of 
HBV-HIV co-infected patients undiagnosed and untreated. Medical practioners 
will benefit from this work, on the basis of increased HBV infection diagnosis 
thus resulting in more favourable therapeutic treatment options for HBV-HIV co-
infected patients. A vast amount of studies attribute non-response or viral-
breakthroughs in ARV treated patients to the use of 3TC. This study will aim to 
provide more information on patterns of 3TC resistance in HIV-positive patients 
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on ART. The possible outcomes of this study will provide significant information 
to both the scientific and medical research communities in South Africa which is 
burdened by infection with sub-genotype A1, whereas previous studies outside 
Africa focus on other strains of HBV. 
 Determine HBV-suppression in response to Lamivudine in HIV-infected 
adults 
 Identify risk factors and markers of viral suppression whilst on 
Lamivudine 
 Determine genotypes and genotypic changes during follow-up 
 Molecular characterisisation of HBV in HBsAg-positive or HBsAg-
negative individuals, pre- and post-initiation of ART 
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CHAPTER 2: MATERIALS AND METHODS 
This study is a laboratory-based follow-up of a study initiated in 2008 (Bell et al., 
2012; Makondo, Bell and Kramvis, 2012). 
 
2.1 Study Participants 
Ethical approval for the study was granted by the Human Research Ethics 
Committee of the University of Witwatersrand and the Mpumalanga Department 
of Health, Republic of South Africa. Inclusion criteria for the study required that 
participants be over the age of 18, HIV-positive and ART-naїve. Enrolment was 
undertaken over an 18 month period and participants were followed-up at 3, 6, 12 
and 18 months after initiation of ART. The National Health Laboratory Service 
(NHLS), hospital and TherapyEdge-HIV (TE)™records were used to obtain 
participant information namely: ALT levels, CD4+ counts, age, sex, height and 
weight. The  298 treatment-naїve individuals, qualified for ART, based on their 
CD4+ counts and HIV viral-loads, as stipulated by the South African Department 
of Health, HIV treatment guidelines at the time (South African National 
Department of Health, 2004). Thus at baseline, subjects were placed on one of 
two ART drug regimens referred to as D001 [Stavudine (D4T) + Lamivudine 
(3TC) and Nevirapine (NCP)] or D002 [Stavudine (D4T) + Lamivudine (3TC) 
and Efavirenz (EFV)]. The South African, Department of Health’s ART 
guidelines have changed to include Tenofovir (TDF), as a replacement for 
Stavudine  (South African National Department of Health, 2010).   
 
Blood samples were collected from participants at enrolment and at each follow-
up time-point at Shongwe Hospital, in rural Mpumalanga province. Of the 298 
HIV-positive participants, 23.83% (71/298) tested positive for HBV DNA in at 
least two of three different genomic regions (Bell et al., 2012; Makondo, Bell and 
Kramvis, 2012). Only 40 of the 71 participants, who tested positive for HBV 
(55%) returned for follow-up at a minimum of one time-point, after initiation of 
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ART. Due to insufficient serum volume, one of the participants in the follow-up 
group could not be included in the present study.  Demographic data, serological 
and clinical laboratory data for 298 HIV-positive participants enrolled in our 
previous study were examined  (Bell et al., 2012; Makondo, Bell and Kramvis, 
2012).  Sera from the 39 follow-up patients were processed for downstream 
analysis of HBV serology and DNA extracted for HBV DNA quantification and 
molecular characterization of HBV 
 
Figure 2.1: Hierarchial division of participants based on HIV-status, HBV-status 
and return for follow-up 
HIV +ve 
Participants            
n = 298
HBV DNA -ve                             
n =227
(76%)
HBV DNA +ve                       
n = 71
(24%)
Did not return 
for follow-up                         
n = 31
(44%)
Returned for 
follow-up                             
n = 39 
(56%)
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2.2 Serology  
Detection of antigens and antibodies were carried out for the baseline samples in 
the initial study (Bell et al., 2012; Makondo, Bell and Kramvis, 2012) and 
subsequently for the follow up samples. HBsAg, anti-HBs, anti-HBc, HBeAg, 
anti-HBe and anti-HBc IgM, were determined using Monolisa™ HBsAg ULTRA, 
HBsAb ULTRA, HBcAb PLUS ELISA, Monolisa™ HBeAg-Ab PLUS (all the 
above mention ELISA kits were from BioRad, Hercules, USA) and 
ARCHITECT® (Peviva AB, Stockholm, Sweden). Antigen and antibody 
detection, together with viral-loads and ALT levels, were used to determine the 
natural history of infection as explained in section 1.4 above.  
 
2.3 DNA Extraction  
The QIAamp DNA Blood Mini-kit (QIAgen Gmbh, Hilden, Germany) was used 
to extract DNA from blood, plasma or serum. The first step of the protocol 
involved adding 20 µl of Proteinase K (provided with the kit), 200 µl of lysis 
buffer and 200 µl of sample, to sterilised 1.5 ml tubes, which were pulse-vortexed 
for 15 sec. The tubes were subsequently heated at 56˚C for 15 min, this step 
allows lysis of cell membranes and degradation of membranous proteins. 
Following the addition of 200 µl of 100% ethanol to each tube, tubes were pulse-
vortexed for 15 sec then incubated for 5 min at room-temperature. Ethanol allows 
the impurities that remain, to become sufficiently soluble to pass through the filter 
in the QIAamp Mini-spin Column®. The mixture was then centrifuged at 3000 
rpm for 1 min. The entire mixture from each tube was carefully transferred to a 
QIAamp Mini-spin Column® and centrifuged at 8000 rpm for 1 min, allowing the 
DNA to adhere to the column membrane. Contents of the collection tubes were 
discarded and the columns placed into clean collection tubes. Column were then 
treated with 500 µl of buffer AW1, allowing purification of the DNA in the 
column. Tubes were centrifuged at 8000 rpm for 1min. The second wash step 
entailed discarding the contents of the collection tubes and placing the columns 
into clean collection tubes, 500 µl AW2 was added to each column, after which 
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the samples were centrifuged at 8000 rpm for 1 min. The use of two different 
wash buffers ensures added purity of the DNA. Columns were moved to new 
collection tubes, then centrifuged at 14 000 rpm for 1 min, to get rid of any excess 
wash buffer. The final steps of DNA extraction involved unbinding DNA from the 
membrane inside the column. Elution buffer (provided with the kit) is generally 
used to suspend and store the DNA, however for the sake of reproducibility and 
comparison the protocol used by Bell et al., 2012 and Makondo, Bell and 
Kramvis, 2012 was replicated. Therefore Best Quality Water (BQW) was used in 
place of the elution buffer. Once 75 µl BQW was added to each column, the 
samples were allowed to incubate at room temperature for 5 min. Columns were 
placed in 1.5 ml storage tubes and centrifuged at 14 000 rpm for 1 min. Extracted 
DNA was stored at -20˚C until further use.  
 
2.4 HBV-DNA Quantification 
Quantative Polymerase Chain Reaction (qPCR) is based on a similar concept as 
conventional PCR (Refer to section 2.5) but with the amplicon labelled with 
fluorescent dyes or probes with fluorescent reporters, these are only detectable 
once they have hybridised to the complementary sequence, sensors detect the 
fluorescence and amplicon is counted at the end of each cycle. A standard curve is 
generated using standards of known concentration, which allows measurement of 
the unknown sample concentration. The HBV qPCR protocol involves 
amplification within the S-region (nt 379-402 from the EcoRI site)    
 
2.4.1 Preparation of Plasmid Standards   
HBV viral-loads were determined using qPCR, the protocol for which, was 
described by (Weinberger et al. 2000). In-house plasmids consisting of a 1.3 mer 
HBV-A1 over-length clone were used to develop standards required for qPCR. 
Plasmids were revived from storage by plating onto an ampicillin containing agar 
plate. Following overnight incubation at 37˚C, a single colony was picked and 
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used to inoculate 5 ml of Luria Bertani (LB) broth containing ampicillin and left 
to incubate overnight at 37 ˚C in a shaking incubator. A 1 ml volume of inoculum 
was used to inoculate 100 ml of LB broth treated with ampicillin was incubated at 
37˚C overnight in a shaking incubator, following which the inoculum was 
centrifuged at  4˚C for 20 min, the supernatant was discarded and a maxi-prep was 
carried out using QIAgen Endo-free Maxi Prep Kit (QIAgen Gmbh, Hilden, 
Germany). A Nanodrop (Thermo Fischer Scientific, USA) was used to measure 
the DNA concentration, thereafter serial dilutions of the plasmids were made 
using elution buffer as the diluent.  
 
2.4.2 Quantification PCR 
A serial dilution of the plasmids with concentrations ranging from 1 × 103 - 1 × 
1010 IU/ ml, was used as standards that were used to generate the standard curve 
(1 x 101 IU/ML and 1 x 102 IU/ml did not produce stable wavelength readings).  
The second Eurohep standard (product code 97/750) from National Institute for 
Biological Standards and Controls (NIBSC); Hertfordshire, UK], with a final 
concentration of 106 IU/ml, was used as the internal standard.      
 
The qPCR reaction mixture consisted of  25 µl 2x EagleTaq Master Mix, 1.5 µl 10 
µM of each primer (Taq 1 and Taq 2), 1 µl 10µM Probe [(FAM-TAMRA labelled 
probe was synthesised by ABI (Applied Biosystems, Carlsbad, California, USA)], 
19 µl BQW and 2 µl BQW. PCR was carried out on the CFX96™ Touch Real-
Time PCR Detection System (BioRad, Hercules, CA). Please refer to Table 2.1 
for probe and primer sequences.  PCR cycling involved 45 cycles at 50 ˚C for 2 
min, 95 ˚C for 10 and 95 for 0.15 sec. Standards were run in triplicate, whilst 
controls and samples were run in duplicate. An R-squared value of > 0.95 was 
achieved for each run. Results were analysed using BioRad’ CFX Real-Time PCR 
Software. 
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Table 2.1 qPCR and BCP/PreC, PCR and sequencing primers and probe 
sequences   
 qPCR Primers and Probes 
Nucleotide Co-
ordinates  
Probe 5’FAM-TCC TCC AAT TTG TCC TGG TTA TCG 
CT-TAMRA3ˈ 
349-375 
Primer 
one 
5’ -CAA CCT CCA ATC ACT CAC CAA- 3ˈ 321-342 
Primer 
two 
5’ -ATA TGATAA AAC GCC GCA GAC AC- 3ˈ 402-379 
 
BCP/PreC PCR and Sequencing Primers  
BCP 1F 5'-GCA TGG AGA CCA CCG TGA AC-3' 1606-1625 
BCP 1R 5'-GGA AAG AAG TCC GAG GGC AA-3' 1955-1974 
BCP 2F 5'-CAT AAG AGG ACT CTT GGA CT-3' 1653-1672 
BCP 2R 5'-GGC AAA AAA  CAG AGT AAC TC-3' 1940-1959 
BCP1 5'-GAG GCA TAC TTC AAA GAC TG-3' 1698-1717 
BCP2 5'-AGT AAC TCC ACA GTA GCT CC-3' 1928-1947 
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2.5 Nested PCR and Sequencing  
2.5.1 BCP/PreC PCR and Sequencing  
This BCP/PreC PCR protocol was developed by Takahashi et al. 1995. The first 
round PCR mixture included; 13.9 µl BQW, 2.5 µl 10x NH4, 1.5 µl 3.0 mM 
MgCl2, 2 µl dNTP’s (200 µM of each), 1.25 µl of each primer (BCP1F and 
BCP1R, refer to Table 2.1 for probe primer sequences), 0.1 µl BIOTAQ enzyme 
(Bioline, London, UK), 2.5 µl DNA with a total reaction volume of 25 µl. PCR 
cycling conditions included, denaturation at 95˚C for 1 min, annealing at 55˚C for 
1 min and extension at 72˚C for 2 min, carried out on the Mastercycler 
(Eppendorf, Germany). 
 
The second round amplification mixture consisted of 29 µl BQW, 5 µl 10x NH4, 
1.5 µl 3.0 mM MgCl2, 4 µl dNTP’s (200 µM of each), 1.25 µl of each primer 
(BCP2F and BCP2R, refer to Table 2.1 for primer sequences), 0.1 µl BIOTAQ  
enzyme (Bioline, London, UK), 2.5 µl DNA with a total reaction volume of 25 
µl.1 PCR cycling conditions included, denaturation at 95˚C for 1 min, annealing 
at 55˚C for 1 min and extension at 72˚C for 2 min, carried out on the Mastercycler 
(Eppendorf, Germany). The sequencing primers used for this region were BCPS1 
and BCPS2.  
 
2.5.2 Complete S PCR and Sequencing 
The second region amplified was the 1203 bp, complete S-region (nt 2848-835 
from the EcoRI site (GAATTC), where the EcoR1 site is used as the first 
nucleotide using the PCR protocol of Vermeulen et al. 2012. The first round of 
PCR consisted of 9.25 µl BQW, 12.5 µl QIAgen Hotstar Master Mix (QIAgen 
Gmbh, Hilden, Germany), 0.375 µl primers (S1F and S1R, refer to Table 2.1 for 
primer sequences), 2.5 µl DNA making up a 25 µl reaction mixture. PCR cycling 
involved 40 cycles of denaturation at 94˚C for 60 sec, annealing at 65˚C for 1 min 
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and extension at 72˚C for 3 min, carried out on a Mastercycler (Eppendorf, 
Germany).   
 
The second round reaction mixture was composed of 18.5 µl BQW, 25 µl QIAgen 
Hotstar Master Mix, 0.75 µl primers (S2F and S2R, refer to Table 2.1 for primer 
sequences), 5 µl DNA making up a 50 µl reaction mixture. PCR cycling involved 
40 cycles of denaturation at 94˚C for 60 sec, annealing at 66˚C for 1 min and 
extension at 72˚C for 3 min, carried out on a Mastercycler (Eppendorf, Germany). 
Three sequencing primers; 2497F, 3188F and 591F, all in the forward direction 
were used in sequencing this region.   
 
The overlapping ORFs of the complete S and Pol regions of the HBV genome, 
allow for analysis of a portion of the Pol gene that overlaps with the complete S-
region. The Pol region spanning from nt 2307 – 1623 (from the EcoR1 site)  
overlaps with the complete S-region which spans from nt 2848 – 835 (from the 
EcoR1 site) (Lin and Kao, 2010), it is within this region that the Spacer and the 
first   236 aa’s of reverse transcriptase overlap with the complete S-region . A two 
nucleotide frame-shift change in the alignment of the complete S-region allows 
for analysis of the Pol region. The complete Pol ORF is not easily amplified due 
to the large size of this gene. 
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Table 2.2 Complete S PCR  and sequencing primer sequences   
 
Complete S PCR and Sequencing Primers 
Nucleotide 
Co-
ordinates 
S1F 
5’ -TCA ATC GCC GCG TCG CAG AAG ATC TCA ATC-3ʹ 2410-2439 
S2F 5’ -TCC AGA CCG/T GCT GCG AGC AAA ACA-3ʹ 1314-1291 
 Complete S PCR and Sequencing Primers  
S2R 
5’ -AAT GTT AGT ATT CCT TGG ACT CAT AAG GTG GG-
3ʹ 
2451-2482 
S2F 
5’-AAT GTT AGT ATT CCT TGG ACT CAT AAG GTG GG-
3ʹ 
1254-1286 
2497F 
5’ -TTC CTT GGA CTC ATA AGG TG-3ʹ 
 
2461-2480 
3188F 5’ -AG TCA GGA AGG CAG CCT AC-3ʹ 3152-3170 
591F 5’ -ATT GCA CCT GTA TTC CCA TCC-3ʹ 591-611 
 
2.6 Gel Electrophoresis and Sequencing   
All PCR products were electrophoresed on a 1% agarose gel in 1 x TBE solution, 
at 85 volts for 45 – 90 min, depending on the size of the amplicon of interest. 
Migration of a 100 bp DNA ladder (Promega, Madison, WI, USA) was used to 
detect the 300 bp BCP/PreC and 540bp P7/P8 PCR amplicons. A 1 kb ladder 
(Promega, Madison, WI, USA) was used to detect the 1200 bp complete S-region 
amplicon. Ultraviolet light was used to visualise samples using the GelDoc 
Imaging System (BioRad, USA). Samples with positive amplification detected, 
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were sent to the Central Analytical Facility, Stellenbosch University, South 
Africa, for PCR clean-up and sequencing. The BigDye Terminator v3.0 Cycle 
Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA) was used 
to prepare amplicons, which were sequenced on the ABI 3130XL Genetic 
Analyser (Applied Biosystems, Foster City, CA).   
 
2.7 Statistical Tools 
The R statistical language was used to perform all statistical test (Team & 
Computing, 2013). Chi-squared, Wilcoxon and one-way ANOVAs were used to 
compare continuous variables. Statistical significance was considered at p <0.05, 
all p-values were two sided. Medians and Interquartile Ranges (IQR) were used to 
analyse and represent data.  
 
2.8 Phylogenetic and Bioinformatic Analyses 
Chromatograms were viewed using FinchTV 1.4.0 (Geospiza, 2009) and 
manually aligned in GeneDoc (Nicholas and Nicholas, 1997). Sequences of the 
complete S-region were assembled using the Fragment Merger Tool (Bell and 
Kramvis, 2013). Alignments were processed through MEGA v6.0 (Tamura et al., 
2013) to construct a neighbour-joining phylogenetic tree using the Kimura 2-
parameter model (Kimura, 1980). Trees were prepared using Pipeline: TreeMail 
(Bell and Kramvis 2015), which uses the PHYLIP package (Felsenstain, 1989)  
and viewed using TreeView 1.6.6. 
(http://taxonomy.zoology.gla.ac.uk/rod/treeview.html). Bootstrapping was 
performed using 1 000 replicates in order to determine the support for the specific 
nodes. Trees were futher analysed and arranged using FigTree (Rambaut, 2012), 
TreeGraph (Müller and Müller, 2004)was use to makes layout changes to the two 
trees constructed. The accession numbers of HBV isolates sequenced in this study 
have been deposited in GenBank.  The Mutation Reporter Tool (Bell and Kramvis 
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2013b) was used to locate relevant mutations at various regions on the HBV 
genome. 
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3. RESULTS:  
Figure 3.1 represents an overview of the structure of the present study. This study 
extended on the baseline work conducted by Bell et al., 2012 and Makondo, Bell 
and Kramvis, 2012.Figure 3.2 summarizes the results in terms of  serological 
groups, virologic suppression and viral breakthrough (VBT) All values presented 
in this study were median values and the 25 percentile – 75 percentile Inter 
Quartile Range [IQR]) values. Significance for this study was set at 0.05.        
 
 Figure 3.1 Study Overview 
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Figure 3.2 Hierarchial Overview of Participant Distribution into study 
groups  
NS: No Suppression  
VBT: Virologic Breakthrough    
HIV +ve 
Participants             
n = 298 
HBV DNA +ve                             
n =227
(76%)
HBV DNA +ve                       
n = 71
(24%)
Did not return 
for follow-up                 
n = 31
(44%)
Returned for 
follow-up                      
n = 39 
(56%)
Full Suppression
n = 10
(26%)
No Suppression     
n = 29 
(74%)
NS VBT +ve                         
n = 10
(34%)
NS VBT -ve                         
n = 19
(66%)
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3.1 Follow-up Visit 
Of 71 HBV-HIV co-infected participants, only 39 returned for visits after 
initiation of ART, representing a 45% loss to follow-up. The reason for the loss to 
follow up included, death, relocation and inability to trace the participant. Table 
3.1 summarises participation in the follow-up visits. The prefix SHH (SHongwe 
Hospital) were used in the participant numbers, the suffixes A, B, C, D and E 
refer to the baseline and four follow-up time-points.   
 
Table 3.1:Summary of participation at each visit 
 
Follow-up visit after 
baseline 
A B C D E 
Median return for follow-
up (months) 
0 4.2 7.4 12 18.2 
No. of participants at each 
visit 
39 31 34 30 29 
Percentage return for 
follow-up 
N/A 79.49% 87.18% 76.92% 74.36% 
 A, B, C, D and E represent baseline and the four follow-up time-points 
 
3.2 Demographic, Clinical, Serological and Virological features of 
Participants 
During the initial study (Bell et al., 2012; Makondo, Bell and Kramvis, 2012), 
HBV viral-load, genotyping and sequence data were generated for all baseline 
samples. Serological laboratory tests for baseline and follow-up samples were 
carried out during the initial study and this data was used in the current study in 
conjunction with all new data obtained.  
 
The median age of the 39 participants at baseline was 34 years (28.5 - 40), 20 
were males. All participants were black southern Africans. The median (IQR) 
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BMI, weight, ALT and CD4+ counts at baseline were, 21.6 (20.15 - 24.4) kg/m2; 
61.4 (53.35 - 71.6) kg; 25 (18 - 42) IU/ml and 148 (80.5 - 201.5) cells/ml, 
respectively (Table 3.2, Column 2). The median baseline and final HBV viral-
loads for all participants were 7.24 x 103 (2.05x103 -3.62x104) IU/ml and 9.36 x 
103 (0 - 1.74x103) IU/ml, respectively. When comparing the percentage change of 
HBV viral-loads between baseline and the final time point, a median decrease of 
47.25% was achieved overall. Refer to the second column in Table 3.2 to find the 
demographic, clinical, serological and virological features of all study 
participants. 
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Table 3.2 Demographic, Clinical and Virological Characteristics of HBsAg+ and 
HBsAg- Groups at baseline and/or the final time-point 
  
All                               
n = 39 
HBsAg+                       
n = 20 
HBsAg-                                                                                              
n = 19                           
P-
value                                            
Demographic and Clinical Characteristics 
Sex                        
(M/F) 
20:19 11:09 08:11 0,27 
Age 
34                             
(28,50 - 40) 
35                                             
(31 - 41,00) 
32                                                          
(28 - 39) 
0,75 
 Baseline                      
ALT 
(normal range  
7-55 u/l) 
25                                     
(18 - 42)  
38                                                  
(23,50 - 60,75) 
20                                                          
(10 - 26) 
0,98 
 Baseline                  
CD4+ count 
148                             
(80,50 - 201,50) 
125                                                
(83,75 - 197,25) 
151                                                  
(84,50 - 224) 
0,90 
Baseline                  
Weight (kg) 
61,4                
(53,35 - 71,60) 
64,5                                            
(59,30 - 77,83) 
56,3                                                   
(51,95 - 64,45) 
0,02 
Baseline BMI 
21,60                          
(20,15 - 24,40) 
22,5                                              
(20,88 - 25,45) 
20,4                                                    
(19,90 - 23,70) 
0,12 
Virologic Characteristics 
Baseline HBV           
Viral Load      
(IU/ml) 
7,24E+03            
(2,05E+03 -            
3,62E+04) 
5,69E+03                           
(1,81E+03 -      
5,14E+04) 
9,47E+03                                     
(4,27E+03 -           
2,43E+04) 
0,82 
Final HBV                      
Viral-Load        
(IU/ml) 
9,36E+01                           
(0 - 1,74E+03) 
1,74E+03                                  
(7,94E+02 -         
3,09E+03) 
0                                                              
(0 - 4,57E+01) 
0,29 
Difference in 
HBV  viral-loads 
between baseline 
and last follow-
up (IU/ml) 
-5,78E+03                           
(-2,64E+04 -       
6,82E+02) 
-2,04E+03                                         
(-3,52E+04 -      
1,35E+02) 
-9,47E+03                                               
([-2,43E+04] -                  
[-4,27E+03]) 
0,82 
Percentage of               
HBV  
Suppression 
achieved (%) 
-47,75                               
([-100] -                                    
[-13,54]) 
-13,54                                                
([-29,65] -           
[0,91]) 
-100                                          
([-100] -                                    
[-59,34])    
0,01
Chi-Square or Fishers Exact were used to test statistical significance  
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3.3 Comparative analysis of HBsAg Positive and HBsAg Negative Groups 
The data presented by Bell et al. 2012, found in the baseline study that of the 298 
Lam treatment-naїve HIV positive study individuals, 71 tested positive for HBV-
DNA by Nucleic-Acid testing (NAT), 26 were HBsAg+ and 45 HBsAg- (Table 
3.3). The participants that were followed up included 16 participants who were 
HBsAg+ and 23 HBsAg- at baseline. Of the HBsAg- participants, 19 remained 
negative throughout follow-up these were defined as the HBsAg- group. The 
remaining 20 participants were HBsAg+ at baseline and/or at one time-point 
during follow-up, are referred to as the HBsAg+ group, nine were HBsAg+ 
throughout the study. Seven participants sero-converted to HBsAg- at a median of 
4.2 (3.9 - 5.9) months, two participants gained the HBsAg at 18.3 (18.25 - 18.5) 
months. Two participants (SHH071 and SHH246) were HBsAg- at baseline, 
thereafter became sero-positive but had retro-converted to HBsAg- by last time-
point (Table 3.3).  
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Table 3.3 HBsAg serological changes observed in the HBsAg+ group during 
the study 
Participant 
number 
A B C D E 
HBsAg+ throughout study 
SHH001 + + + ND ND 
SHH109 + + ND ND ND 
SHH100 + ND + + + 
SHH126 + + + ND ND 
SHH148 + + + + + 
SHH156 + + + + + 
SHH240 + + ND ND ND 
SHH256 + ND + + + 
SHH300 + + + + + 
Seroconverted from HBsAg+ to HBsAg- 
SHH002 + - - ND - 
SHH016 + - - - - 
SHH042  + - - - - 
SHH070 + - - - - 
SHH159 + + + + - 
SHH180 + - - ND - 
SHH274 + + - - ND 
Median time of seroconversion 4.2 (3.9 - 5.9) months 
Participant 
number 
A B C D E 
Seroconverted from HBsAg- to HBsAg+ 
SHH053 - - - - + 
SHH221 - - - - + 
Median time of seroconversion 18.3 (18.25 - 18,50) months 
Seroconverted from HBsAg- to HBsAg+ to HBsAg- 
SHH071 -   + - ND 
SHH246 - + ND - ND 
 
Baseline weight was significantly higher in the HBsAg+ group (64.5 [59.30 – 
77.83] kg) compared to the HBsAg- group (56.3 [51.95 – 64.45] kg) (p=0.02) 
(Table 3.2). Another significant finding between these two HBsAg serological 
groups, was a higher viral suppression achieved in the HBsAg- group (-100% [(-
100%)–(-59%)]), with the HBsAg+ group achieving -13.54% ([-29.65%] - 
[0.91%]) HBV suppression (p = 0.01) (Table 3.2). Although HBV viral-loads at 
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baseline were indistinguishable between the HBsAg+ (5.69 x 103 [1.81 x 103 – 
5.14 x 104])IU/ml and HBsAg- (9.47 x 103 [4.27 x 103 – 2.43 x 103]) IU/ml 
groups (Figure 3.3), the final HBV viral-load for the HBsAg- group was lower 0 
[0 - 4.57x101] IU/ml than the final viral-load of the HBsAg+ group which was 
1.74 x 103 [7.94 x 102 - 3.09 x 103] IU/ml, however, this was not a significant 
finding (p = 0.81) (Table 3.2).   
 
 
Figure 3.3 Scatter Plot of Baseline and Final HBV viral-loads of participants 
who were HBsAg + or HBsAg- at baseline   
 
3.4 Comparison of Full Suppression (FS) and No Suppression (NS) Groups 
Full suppression was defined as an HBV viral-load equivalent to zero IU/ml by 
qPCR amplification, and which was maintained throughout the study after 
clearance of the virus. Participants were classified as NS if they met one of the 
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following two criteria: i) a participant did not fully clear the virus at any time 
point in the study,  ii) the participant experienced a full suppression followed by 
the detection of HBV by qPCR. Ten participants experienced full suppression of 
HBV, after 17.5 (12.43 - 18.2) months on ART.  All participants that experienced 
full suppression were HBsAg-, which was a significant finding, indicating that 
HBsAg negativity is a predictor of full suppression of HBV(p = 0.01).  
 
Participants in the FS group had significantly lower ALT levels (15.5, [6 - 23.75]) 
at baseline compared to the NS group (35, [8 - 55]) (p=0.02) (Figure 3.4). The FS 
group had a median final HBV viral-load of zero, this was significantly lower than 
the NS group (8.32 x 102 [0 – 2.42 x 103]) (p = 0.01) ( Figure 3.5). The HBV 
viral-loads between these two groups were comparable at baseline (FS: (7.32 x 
103 [4.2 x 103 – 1.78 x 104]), NS: (7.24 x 103 [3.01 x 102 – 6.07 104])) but not at 
the final time-point (Figure 3.5)  Seven participants in the NS group completely 
suppressed the HBV virus before experiencing a VBT. A -100% viral suppression 
was achieved by the FS group whereas the NS group achieved a significantly 
lower percentage of viral suppression with a median -24.02% ([-100%] - [-
5.03%]) (p = 0.01) (Figure 3.6).  
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Table 3.4 Demographic, Clinical and Virological Characteristics of the Full 
Suppression and No Suppression Groups at baseline and/or the final time-points 
  
All                                     
n = 39 
FS                                                          
n = 10 
NS         
n = 31  
P-value                                             
(CI:95%) 
Demographic and Clinical Characteristics 
Sex (M/F) 20:19 4/6 15/14 0,79 
Age 
34                                 
(28,50 - 40) 
30,5                                                                                                
(7,25 - 45) 
35                                                               
(18 - 39) 
0,82 
 Baseline        
ALT 
(normal range  
7-55 u/l)  
25                                     
(18 - 42)  
15,5                                                      
(6 - 23,75) 
35                                                                  
(8 - 55) 
0,02 
 Baseline       
CD4+ count 
148                             
(80,50 - 201,50) 
168,5                                                  
(88 - 229) 
113                                                                
(9 - 196) 
0,53 
Baseline     
Weight (kg) 
61.4                    
(53,35 - 71,60) 
56                                                   
(50,43 - 61,85) 
63,3                                                   
(37,9 - 72,4) 
0,07 
Baseline BMI 
21,60                          
(20,15 - 24,40) 
20,35                                          
(19,95 - 21,73) 
22,4
(13,6-26,2) 
0,13 
Virologic Characteristics 
Baseline HBV 
Viral Load                   
(IU/ml) 
7,24E+03            
(2,05E+03 -                        
3,62E+04) 
7,32E+03                                     
(4.2E+03 -                           
1.78E+04) 
7,24E+03                                 
(3,01E+02 -                           
6,07E+04) 
0,99
Final HBV  
Viral-Load 
(IU/ml) 
9,36E+01                           
(0 - 1,74E+03) 
0 
8,32E+02                                               
(0 - 2,42E+03) 
0,01 
Difference in 
HBV viral-loads 
between 
baseline and last 
follow-up 
(IU/ml) 
-5,78E+03                           
(-2,64E+04 -                                      
6,82E+02) 
-7,32E+03                                             
([-1,78E+04] -                                                   
[4,2E+03]) 
-5,78E+03                                  
([-4,74E+07] -                       
[-4,98E+02]) 
0,54
Percentage of 
HBV 
Suppression 
achieved (%) 
-47,75                                  
([-100] -                                       
[-13,54]) 
-100
-24,02                                                            
([-100,00] -                  
[-5,03]) 
0,01 
FS: Full Suppression                                                                                                                                                                    
NS: No Suppression                                                                                                                                                                                                                                                                                                                                                                                                                        
P-values were calculated using Chi-Square or Fisher's Exact                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
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Figure 3.4 A whisker-box plot comparing baseline ALT levels between the 
Full suppression (FS) and No suppression (NS) groups. Lower baseline ALT 
levels were observed in the FS group compared to the NS group. 
 
 
Figure 3.5 Comparison of baseline and final viral-loads among the different 
suppression groups. This figure shows that the baseline viral-loads were 
comparable among all groups. 
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Figure 3.6 A whisker-box plot comparing percentage viral suppression 
achieved between the FS and NS groups. The NS group had only a 40% viral 
suppression during the study compared to a 100% viral suppression achieved 
by the FS group 
3.5 Comparison of the NS VBT+ and NS VBT- Groups 
A virologic breakthrough (VBT) is defined as a >1 log increase in viral load after 
nadir (Hongthanakorn et al., 2011).  The HBV virus was not adequately 
suppressed in 19 participants, of which, 10 experienced a VBT, referred to as NS 
VBT+. A higher frequency of VBT occurred among the HBsAg- participants, 
which accounted for 7 of the 10 VBTs.  Median time between initiation and nadir 
was 5.1 (3.6-8.2) months. Participants in the NS VBT+ group experienced a VBT 
12.35 (6.5-18.23) months after initiating ART and 5.3 (2.3-10.28) months after 
nadir. Furthermore, all seven HBsAg- participants that fully suppressed HBV and 
experienced a VBT ultimately showed full suppression. Although the NS VBT+ 
group had higher baseline ALT levels (38, [22.5-37.75] IU/ml) than the NS VBT- 
group (35 [20 – 57.5] IU/ml, this was not significant (p = 0.60) (Table 3.5). 
Interestingly the NS VBT+ group had a significantly higher percentage of viral 
suppression (Figure 3.7) , (-51,90% [-59,61] -[-41,37]),  compared to the NS 
VBT- group -14,35% ([-47,14%] - [-0,73%]), despite the VBT events (p = 0.03).  
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Table 3.5 Demographic, Clinical and Virological Characteristics of NS VBT+ and NS VBT- 
Groups at baseline and/or the final time-points 
  
All                                
n = 39 
NS VBT+                   
n=10 
NS VBT-                            
n=17 
P-value 
(CI:95%) 
Demographic and Clinical Characteristics 
Sex (M/F) 20:19 6/4 15/14 0,8 
Age 
34                                 
(28,50 - 40) 
30                                          
(27,25 - 38,25) 
35                                      
(33,5 - 39) 
0,21 
 Baseline                              
ALT             
(normal range      
7-55 u/l) 
25                                     
(18 - 42)  
25,5                              
(22,25 - 37,75) 
35                                             
(20 - 57,5) 
0,6 
 Baseline                     
CD4+ count 
148                             
(80,50 - 201,50) 
130,5                                             
(80 - 166,75) 
110                                      
(92,5 - 201,5) 
0,57 
Baseline                             
Weight (kg) 
61,4                    
(53,35 - 71,60) 
65,65                                 
(53,9 - 71,8) 
63,2                                         
(56,65 - 80,35) 
0,67 
Baseline BMI 
21,60                          
(20,15 - 24,40) 
21,95                                    
(20,03 - 25,78) 
22,60                                  
(20,65 - 26,3) 
0,62 
Virologic Characteristics 
Baseline HBV    
Viral Load                   
(IU/ml) 
7,24E+03            
(2,05E+03 -                           
3,62E+04) 
5,64E+01                         
(4,37E+01 -                     
1,75E+03) 
1,25E+03                          
(3,19E+02 -                                
2,47E+03) 
0,16
Final HBV        
Viral-Load       
(IU/ml) 
9,36E+01                           
(0 - 1,74E+03) 
5,64E+01                 
(4,37E+01 -                                 
1,75E+03) 
1,25E+03                           
(3,19E+02 -                                               
2,47E+03) 
0,09
Difference in           
HBV viral-loads 
between baseline 
and last follow-up 
(IU/ml) 
-5,78E+03                           
(-2,64E+04 -                               
6,82E+02) 
-2,22E+04                                
([-6,16E+04] -                                                
[-2,48E+03]) 
-3,30E+03                                    
([-1,75E+04] -                              
[-4,76E+00]) 
0,23
Percentage of  
HBV Suppression 
achieved (%) 
-47,75                                  
([-100] -                                          
[-13,54]) 
-51,90                                       
([-59,61] -                                   
[-41,37]) 
-14,35                                        
([-47,14] -                                             
[-0,73]) 
0,03
NS VBT+: No Suppression Virologic Breakthrough Positive                                                                                                                                                                                                                                                                                                                                                                             
NS VBT-: No Suppression Virologic Breakthrough Negative                                                                                                                                                                                                                                                                                                                                                                                                                       
P-values were calculated using Chi-Square or Fisher's Exact                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
Significant findings are highlighted in bold                                                                                                                                               
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Figure 3.7 Percentage viral suppression achieved in the NS VBT- and NS VBT+ 
groups. Despite the virological breakthrough event in the NS VBT+ group this 
group achieved a viral suppression of 40 -60% whilst the NS VBT- group only 
experienced  a viral suppression of approximately 20% 
 
3.6 Occult and Covert Infection 
Occult HBV Infection (OBI) is defined by serum HBV-DNA viral-loads of ≤ 200 
IU/ml in the absence of HBsAg (Raimondo et al., 2008). Covert (false occult) 
infection is defined by HBV viral-loads >200 IU/ml in HBsAg- individuals (Bell 
et al., 2012). Prior to initiation of ART all study participants, who were followed 
up in the HBsAg- group were coverts. Four participants (SHH053A, SHH071A, 
SHH221A and SHH246A) in the HBsAg+ group were coverts at baseline as they 
were HBsAg- at this time-point, the remaining were overts (HBsAg+ with 
detectable HBV DNA in serum). No occult infection was found at baseline.  
At the last follow-up, four HBsAg+ participants, sero-converted to HBsAg- and 
were now classified as covert infected, as they had viral-loads >200 
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IU/ml.SHH246 was HBsAg- at both baseline and the final time-points but was 
HBsAg+ at time-point “B” therefore was included in the HBsAg+ group. In the 
HBsAg- group, 13 participants completely suppressed the virus at the final time-
point of these seven experienced a VBT during the study. Six participants in the 
HBsAg- group were covert at baseline but occult at the last follow-up.  
 
Table  3.6 Summary of HBV covert and occult infection using the baseline and 
final viral-loads and HBsAg sero-status 
    
Baseline HBV                
Viral Load (IU/ml 
  
Final HBV                 
Viral Load (IU/ml) 
  
H
B
sA
g
+
 
SHH126 4,78E+02   1,76E+03   
SHH148 1,65E+03   1,73E+03   
SHH156 8,33E+04   4,28E+02   
SHH159 4,74E+07   1,02E+04 covert 
SHH180 7,94E+03   2,53E+03 covert 
SHH221 1,86E+03 covert 1,27E+03   
SHH240 8,44E+02   1,25E+03   
SHH246 9,57E+02 covert 1,84E+02 covert 
SHH256 2,64E+04   5,23E+01   
SHH274 3,11E+05   6,80E+02 covert 
SHH300 3,01E+02   2,10E+02   
H
B
sA
g
- 
SHH024 2,66E+04 covert 5,96E+01 occult 
SHH029 1,14E+09 covert 0,00E+00   
SHH032 1,26E+03 covert 5,32E+01 occult 
SHH037 2,97E+06 covert 4,47E+01 occult 
SHH041 6,07E+04 covert 9,36E+01 occult 
SHH045 6,33E+03 covert 4,68E+01 occult 
SHH052 5,41E+02 covert 4,26E+01 occult 
SHH054 5,16E+03 covert 0,00E+00   
SHH074 9,47E+03 covert 0,00E+00   
SHH110 1,01E+04 covert 0,00E+00   
SHH173 5,86E+03 covert 8,30E+01   
SHH193 4,39E+03 covert 0,00E+00   
SHH194 1,79E+04 covert 0,00E+00   
SHH213 2,20E+04 covert 0,00E+00   
SHH214 1,05E+03 covert 0,00E+00   
SHH219 1,98E+03 covert 0,00E+00   
SHH222 2,04E+04 covert 0,00E+00   
SHH264 9,02E+06 covert 0,00E+00   
SHH270 4,14E+03 covert 0,00E+00   
Highlighted in green are the covert infections                        
Highlighted in purple are the occult infections                                    
Some HBsAg+ partipants were HBsAg at certain time-points 
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3.7 Genotyping 
3.7.1 Genotyping using the BCP/PreC region 
The baseline study (Bell et al., 2012) found five HBeAg+ participants. Ten 
participants in the follow-up study were HBeAg+ for at least one time-point 
during the study (Table 3.9). Mutations in the BCP/PreC region coding for 
HBeAg were investigated, comparing mutations found in the HBeAg+ group with 
the HBeAg- group. Analysis of positions 1809-1812, 1858 and 1888 (from the 
EcoR1 site) (Figure 3.8) within the BCP/PreC region of HBV was used to 
distinguish genotypes and subgenotypes.  
 
Table 3.7 HBeAg positive participants and the HBeAg serological 
changes observed during the study 
Participant Time-points 
Number A B C D E 
SHH002 - - - - + 
SHH037 - - + ND ND 
SHH100 - - + - - 
SHH110 - - ND - + 
SHH126 - + ND ND - 
SHH159 + + + + - 
SHH180 - - + - - 
SHH193 - - - + + 
SHH214 - + ND + - 
SHH274 + + - - - 
 
 
The presence  of 1809TCAT1812, C1858 and A1888 ,characteristicof subgenotype 
A1(Kimbi et al., 2004; Tanaka et al., 2006) was found in 71 of BCP/PreC 
sequences. Whilst isolate SHH032A, SHH042D and SHH274D had 
1809GCAC1812, C1858 and G1888, these are consistent with subgenotype A2. 
Phylogenetic analysis of the complete S-region sequences with reference 
sequences of subgenotype A1 and A2 showed that isolates SHH032A, 
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SHH042Dand SHH274D clustered with subgenotype A1. Discordant results were 
also found in isolates SHH016A, SHH042A and SHH159D which displayed 
characteristics of non-A genotype with 1809GCAC1812, T1858 and A1888. 
However the sequences from isolates of both these isolates clustered with 
subgenotype A1, during phylogenetic analysis of the S region. HBV isolate 
SHH053A showed non-A infection by BCP/PreC genotyping, this was confirmed 
as genotype E infected by complete S region phylogenetic analysis. Additional 
discordant findings were found in isolate SHH173A, which clustered distinctly 
with subgenotype D3 upon a phylogenetic analysis of the complete S sequences, 
however, the BCP/PreC analysis showed subgenotype A1 characteristics. These 
discordant findings could not be further analysed without cloning or full-
lengthsequencing, because this was outside the scope of this study.    
 
Table 3.8 BCP/PreC Loci 1809-1812, 1858 and 1888 used to genotype HBV 
sequences, including Non-A1 isolates from this study 
 
BCP/PreC Loci (numbered from the EcoR1 site) 
 
 
1809 - 18012 1858 1888 
HBV Subgenotype A1 TCAT C A 
HBV Subgenotype A2 GCAC C G 
HBV Genotype Non-A GCAC T G 
 
 
3.7.2 Phylogenetic Analysis 
Amplification of the complete S-region (nt 2854 – 835 from the EcoR1 site) 
yielded 47 sequences. Fourteen of these sequences were from baseline samples, 
and the remaining from follow-up time-points.  Fifteen baseline sequences and 24 
follow-up sequences were from the HBsAg+ group. These sequences were used to 
construct a neighbour-joining phylogenetic tree (Figure 3.9). Bootstrapping of 
1000 replicates was used to test the statistical support of relatedness of isolates in 
the tree. The complete S region sequences are preferred for use of HBV 
phylogenetic analyses as the region is sufficient in length allowing for statistical 
63 
 
robustness and the region is small enough to produce more amplicon than full 
genome amplification.  
 
Analysis of the tree constructed with genotypes and subgenotype A-H, revealed 
that isolate SHH053Abelonged to genotype E at baseline. This isolate clustered 
with subgenotype A1 at the first follow-up. Genotyping of the third, fourth and 
fifth follow-ups was completed using the BCP/PreC sequences as no further 
complete S amplicon were generated for HBV isolated from isolate SHH053. 
BCP/PreC loci indicated that isolate SHH053 was infected with HBV 
subgenotype A1 at time-points ‘A’, ‘B’ and ‘C’ (Figure 3.10 BCP Genotyping). 
Isolate SHH173A clustered with subgenotype D3 at baseline.  No further S region 
sequences were available for phylogenetic analysis. However at the 6 
monthfollow-up point, from the BCP/PreC sequences available the HBV isolated 
belonged to subgenotype A1. The 45 remaining sequences   clustered with 
subgenotype A1. In summation, other than isolates SHH053A and SHH173A all 
other isolates belonged to sub-genotype A1.  
 
Isolates; SHH002, and SHH070 complete S region sequences from follow-up 
clustered together but the baseline sequences belonged to different clades. This 
was more evident in some isolates (SHH159, SHH256 and SHH300), in which the 
follow-up sequences clustered together but distantly from the baseline sequences. 
This could be caused by selection pressure under which the wild-type is 
susceptible to Lam, therefore quasispecies diversity post-treatment appears to be 
highly divergent compared to baseline pretherapy sequences.  
 
HBV sequences isolated from SHH300 at baseline and last follow-up show more 
homogeneity whilst isolates SHH300B+D, (which clustered separately from 
SHH300A+E, see Figure 3.), showed more homogeneity. Upon mutational 
analysis of the BCP/PreC, complete S and polymerase regions, isolates 
SHH300A+E showed distinct similarities in sequences indicating that at the last 
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follow-up this isolate was reverting to a baseline sequence indicating that 
treatment was no longer able to efficiently suppress HBV (SHH300 belonged to 
NS VBT- group). This adds to the interpretation that the wild-type (pre-treatment) 
HBV strains in this study may have a susceptibility to Lam, causing the 
emergence of a strain that can withstand Lam treatment. However without further 
amplification, cloning and sequencing it is difficult to ascertain the quasispecies 
evolutionary diversity and complexity. 
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Figure 3.8 A neighbour-joining phylogenetic tree with 1000 bootstrap replicates 
was constructed to determine the genotypes or subgenotypes of participants in this 
study. The majority of HBV isolates belonged to Subgenotype A1 except 
SHH173A and SHH053A which belonged to genotypes D and E, respectively 
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Figure 3.9 (this phylogenetic tree is the same as figure 3.8) This figure shows the 
changes in genotypes or clades of isolates at different time-points. SHH053A 
belonged to genotype E but SHH053B belonged to subgenotype A1. SHH300A 
and E clustered together the same finding was observed for SHH001A and B, 
SHH042D and E, SHH070C and E, SHH100A,C,D and E, SHH148A and E, 
SHH159B and E, SHH300A and E as well as SHH300B and D, 
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3.8 Molecular Analysis  
3.8.1 Mutations in BCP/PreC Region 
There are numerous mutations found in the BCP/PreC region that prevent 
secretion of HBeAg. HBeAg known for its immune-tolerogenic properties allows 
the virus to establish an infection. Ten isolates were HBeAg+ at a minimum of 
one time-point during the study.  Two isolates SHH159 and SHH274 were 
HBeAg+ positive at baseline, seroconversion occurred at time-points E and C, 
respectively. Most mutations were detected at baseline, decreasing at each follow-
up but this could be as a result of the loss to follow-up, as not every subject 
returned at each follow-up time point.  Various loci (nt 1762, 1764, 1809-1812, 
1814-1816, 1862 and 1888) of interest in the BCP/PreC region from nt 1750-1900 
(from the EcoR1 site) were investigated. Mutations at these loci lead to down-
regulation or prevention of HBeAg synthesis or secretion. 
 
The A1762T/G1764A double mutation associated with a reduction of 
transcription was found in HBV isolates from five strains (SHH148A+E, 
SHH180A, SHH221A, SHH264A and SHH300E). Four A1762T/G1764A 
mutations occurred at baseline and twice at 18 months. A G1764A mutation 
occurred once in the absence of the A1762T mutation, in isolate SHH240A (Table 
3.10, Appendix B).  
 
Subgenotype A has a unique Kozak sequence 1809TCAT1812, whereas in other 
genotypes 1809GCAC1812 is found in this region.The 1809GCAC1812 mutation on 
Kozak region occurred in seven HBV subgenotype A1 isolates from theHBeAg- 
group, of which five mutations were found at baseline. The genotype E isolate 
SHH053A had the 1809GCAC1812Kozak sequence. One HBeAg+ isolate 
(SHH159A) had the 1809GCAC1812 mutation in this region (Table 3.9, Appendix 
B).1809TCAC1812 was found at baseline and at the 18 -month follow-up in HBV 
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from SHH148. Mutations 1809TCCT1812, and 1809ACAT1812) were found in isolates 
SHH240A and SHH300A, respectively.   
 
Three isolates (SHH001A, SHH070A and SHH221A) had HBV 
with1814CTG1816precore start codon mutations at baseline only. In isolate SHH148 
an 1814AAG1816 start codon mutation was found at baseline and the last follow-up 
visit, whereas in SHH300 the 1814ACG1816 was found also at baseline and the last 
follow-up visit.Of interest, the 1814ACG1816 start codon mutation was present in 
HBV isolateSHH274, at baseline when the individual was HBeAg+.  
 
This PreC start codon mutation was found in one HBeAg+ isolate, SHH173A. 
The G1862T mutation was observed in nine HBeAg- isolates and three HBeAg+ 
isolates. The mutation occurred in five isolates from five baseline, thereafter was 
found in eight isolates from follow-up. This mutation found to be significantly 
higher in the HBsAg- individuals in the initial study (Makondo, Bell and Kramvis, 
2012), but could not be determined for the follow-up study as the number of 
sequences per group were insufficient, to conduct statistical significance 
calculations. 
 
A1888T occurred once during this study, at baseline isolate SHH070A belonging 
to the HBeAg- group. A1888G of HBV was found in seven baseline isolates, two 
of which were HBeAg+. Of the five follow-up A1888G mutations, one isolate 
belonged to HBeAg+ group. Twelve isolates with BCP/PreC mutations were 
wild-type. The BCP/PreC region had numerous mutations in this study which can 
be correlated to the high prevalence of HBeAg- infections found in the Southern 
African HBV subgenotype A1 strain, however the significance of these findings 
could not be determined as the number of isolates in the follow-up groups were 
insufficient for statistical analysis. Isolate SHH053A belonging to genotype E had 
HBV with1809GCAC1812 Kozak sequence, as well as C1858T, G1862T and 
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A1888T. SHH173A belonging to subgenotype D3 had only the G1862T mutation 
in the BCP/PreC region in HBV isolated at this time-point. 
 
3.8.2 Complete S Region Analysis 
Amplification of the complete S-region (nt 2854 – 835 from the EcoR1 site) 
yielded 47 sequences. Twenty-three of these sequences were from baseline 
samples, and the remaining from follow-up time-points. Fifteen baseline 
sequences and 24 follow-up sequences were from the HBsAg+ group Table 3.3. 
These sequences were used to construct a neighbour-joining phylogenetic tree 
(Figure 3.8 and 3.9). Lower viral loads in the follow-up samples of the HBsAg- 
group can account for the fewer sequences in this group.    
 
 
3.8.2.1 PreS1 Mutations 
The I48V mutation was found in ten HBsAg+ isolates and one HBsAg- isolate 
this was associated with T90V/L/A/K in 17 HBsAg+ isolates and four HBsAg- 
(Table 3.10). In addition, ten V88A/L/K mutations were found in HBV from 
HBsAg+ isolates and HBV from two HBsAg-. Nine P94T mutations were found 
in HBV isolates in the HBsAg+ group and one isolate in the HBsAg- group. Other 
PreS1 mutations found during this study were S5T/N/L, F25L and L85V/M. In 
SHH053A infected with genotype E, the following PreS1 mutations were found 
I48N, V88L and T90A. HBV isolate from SHH173A, infected with subgenotype 
D3 had S5G, I48N V88L and T90A, this participant was HBsAg+ at this time-
point. 
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Table 3.10 Complete S and Polymerase mutations at baseline and follow-up 
  Mutation 
HBsAg + Group HBsAg- Group 
Percentage Frequency of 
Mutation (%) 
Percentage Frequency 
of Mutation (%) 
A B C D  E A B C D E 
n=15 n=8 n=7 n=5 n=6 n=8 
n
=
0 
n
=
0 
n
=
0 
n=
0 
P
re
S
1
 
S5T/N/L 6.7 0 0 0 16.7 25.0         
F25L 26.7       16.7 25.0         
I48V/T 26.7 75.0 80.0 20.0 50.0 62.5         
L85V/M 6.7     40.0 16.7           
V88A/L 46.7 12.5   60.0 16.7 37.5         
T90V/L/A/
K 
80.0 100 80.0 80.0 50.0 87.5         
P94T 26.7 12.5 20.0 20.0 33.3 12.5         
P
re
S
2
 
M1I/L 20.0 12.5 20.0 20.0 3.3 12.5 
    
A7T 40.0 75.0 80.0 20.0 83.3 37.5 
    
Q10K/R 26.7 
   
16.7 25.0 
    
A11T 26.7 12.5 
  
16.7 37.5 
    
F22L 46.7 25.0 20.0 20.0 33.3 12.5 
    
L32H/R 33.3 12.5 
 
60.0 
 
25.0 
    
R48K/T 46.7 25.0 
 
60.0 16.7 25.0 
    
A53V 20.0 
  
80.0 16.7 25.0 
    
L54P 46.7 75.0 80.0 20.0 66.7 37.5 
    
H
B
sA
g
 
V14G/A 20.0 
   
16.7 
     
I68T 6.7 
  
60.0 16.7 12.5 
    
Y100C 
     
12.5 
    
S117N 
     
12.5 
    
T118K 
     
12.5 
    
Q129R 
     
12.5 
    
N131K 6.7 
    
12.5 
    
V168A 20.0 12.5 
   
25.0 
    
S174N 
     
25.0 
    
I195M 
     
12.5 
    
Y206C 
    
16.7 
     
P
o
ly
m
er
a
se
 
E1D 33.3 
    
12.5 
    
S105T 26.7 
    
12.5 
    
H122I/L/N 26.7 
    
37.5 
    
Q125E 53.3 
         
T128N 6.7 
         
L129M/V 6.7 
    
25.0 
    
L180M 
     
12.5 
    
M204I/V 6.7 
    
12.5 
    
 
71 
 
3.8.2.2 PreS2 Mutations 
The M1I/L/T stop codon translation mutation in the PreS2 region, resulting in 
vaccine-escape, was observed in HBV from eight HBsAg+ isolates and one 
HBsAg- isolate (Table 3.11). This amino-acid was lost in one isolate (SHH180A) 
due to a deletion in this region. Sixteen isolates belonging to the HBsAg+ group 
had HBV isolates with the A7T mutation whilst two isolates from the HBsAg- 
group had this mutation. Four isolates of the HBsAg+ had a deletion of 7 aa of the 
PreS2 region. All, but one isolate/s with the A7T mutation were associated with 
the L54P mutation. Other PreS2 mutations found were Q10K/R, A11Tand A53V. 
Five HBsAg+ HBV isolates and one HBsAg- isolate had deletions at aa 22 of the 
PreS2 region. The F22L mutation was observed in nine HBV isolates belonging to 
the HBsAg+ group. PreS2mutation L32H occurred in eight isolates from the 
HBsAg+ group, however, a different mutation L32R was observed in one HBsAg- 
isolate. The L32H mutations in the HBsAg+ group were associated with R48K/T 
in all isolates. The R48K/T mutation ‘alone’ was found in an additional five 
HBsAg+ and two HBsAg- isolates. The genotype E isolate, SHH053A, had the 
following PreS2 mutations, A7T,L32V and T54P while the genotype D isolate , 
SHH173A, had  A7T, L32V and  A11T in the PreS2 region of the isolated HBV.      
 
 
3.8.2.3 HBsAg Mutations  
The S-region from nt 155 – 835 (using the EcoR1 site) was the most well-
conserved region of the three S -regions, with the least number of mutations found 
in this portion of the complete S (Table 3.11). The following mutations, V14A/G, 
I68T and Y206C were observed in HBV isolates in the HBsAg+ group. Isolates 
belonging to the HBsAg- group had mutations Y100C, S117N, T118K, Q129R, 
K131N, S174N and I195M. The A168V mutation was observed in six HBsAg+ 
and two HBsAg- HBV isolates. The significance of mutational frequencies 
between the HBsAg+ and HBsAg- groups could not be determined.  
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3.8.2.4 PreS1/PreS2 Deletion Mutants 
Deletions of up to 33 can be found in the PreS1 and PreS2 regions, in this study 
six HBV isolates had PreS1 and/or PreS2 nucleotide deletions. SHH053 had a 3 
nucleotide deletion at baseline, from nt 2853 – 2855 (using the EcoR1 site) 
Table.). This deletion is found in Genotype E sequences, which was the genotype 
this isolate belonged to at this time-point which was confirmed by phylogenetic 
analysis. At the first follow-up time-point (B) isolate SHH053 had a 33 nt in the 
PreS2 region from nt 13 – 45 (From the EcoR1 site) however at this time-point the 
isolate belonged to HBV subgenotype A1 (Figure 3.). SHH053 was HBsAg- at 
both these time-points but no further complete S sequences were available for this 
isolate. A 119 nucleotide deletion from nt 3135 – 30 (from the EcoR1 site) was 
found in HBV from SHH180 at baseline. This lead to a 21 aa deletion in the 
PreS1 region not causing any deletions at important loci, however in the PreS2 
region deletions of approximately 33nt affecting aa positions 1, 7, 10 and 11. At 
baseline,an HBsAg- isolate (SHH240) had a 32 nucleotide deletion in the PreS2 
region from nt 10 – 42 (from the EcoR1 site). Another PreS2 deletion of 34 
nucleotides from nt 1 – 34 (from the EcoR1 site), was observed in isolate SHH274 
at baseline, at which time the participant was HBsAg+. SHH300, an isolate from 
the HBsAg+ group,  had a 53 nucleotide deletion in the PreS2 region from nt 1 – 
53 (from the EcoR1 site) at baseline and a 52 nucleotide from nt 1 - 52 (from the 
EcoR1 site) at the 18-month follow-up time-point. SHH300 was HBsAg+ at all 
time-points, despite these deletions.    
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Table 3.11 Analysis of PreS deletion mutants 
Isolate 
number 
Nucleo
tide 
positio
n 
Number 
of 
nucleoti
des 
deleted 
Amino-acid 
position 
Number 
of 
Amino-
acids 
deleted 
Functional Domain 
affected by deletions 
SHH05
3A 
2853 - 
2855 
3 PreS1 G2 1 
Myristolated N-
Terminal Glycine 
SHH05
3B 
13 - 45 33 PreS2 12L - 23P 11 B and T cell epitopes 
SHH18
0A 
3135 - 
30 
119 PreS1 97T - 119A 21 
B and T cell epitopes 
      PreS2 1M - 18R 18 
SHH24
0A 
10 - 42 33 PreS2 11A - 22F 11 B and T cell epitopes 
SHH27
4A 
1 - 34 34 PreS2 4N - 19G 12 
B and T cell epitopes, 
pHSA binding site 
SHH30
0A 
1 - 53 53 PreS2 4N - 22F 18 
B and T cell epitopes, 
pHSA binding site 
SHH30
0E 
1 - 52 52 PreS2 5S - 23P 18 
B and T cell epitopes, 
pHSA binding site 
Nucleotides were numbered using the EcoR1 site 
 
 
3.9 Polymerase Mutations 
The overlapping ORFs of the HBV genome allow for analysis of a portion of the 
Pol gene that overlaps with the complete S-region. The Pol region spanning from 
nt 2307 – 1623 (from the EcoR1 site)  overlaps with the complete S-region which 
spans from nt 2848 – 835 (from the EcoR1 site) (Lin and Kao, 2010), it is within 
this region that the Spacer and the first   236 aa’s of reverse transcriptase overlap 
with the complete S-region . A two nucleotide frame-shift change in the alignment 
of the complete S-region allows for analysis of the Pol region. Mutations within 
the spacer region, whose function is not clearly defined, are well-tolerated and 
donot affect polymerase activity. Ten aa lociof interest in the reverse transcriptase 
region were investigated for mutations.   
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The rtE1D start codon mutation together with S105T and H122N occurred in five 
sequences (SHH173A, SHH240A, SHH274A and SHH300A and SHH300E). 
SHH173A was the only isolate of the HBsAg- group found to have a mutation in 
the Pol region. Isolates SHH300A+E showed almost identical sequences at 
baseline and the final time-point, this was also found when analysing the BCP and 
complete S regions.  In isolate SHH180A the rtE1D was found in conjunction 
with Q125E and L129V (Table 3.10). The Q125E mutation was found in 5 
isolates (SHH071A, SHH109A, SHH159A, SHH159D, SHH180A, SHH256D, 
SHH300B and SHH300D), all of these were HBsAg+ isolates however this was 
not a significant finding (p = 0.29) in comparison to the HBsAg- group. Only one 
of these participants experienced a VBT. 
 
The rtL180M drug resistance mutation was found only once during the study, 
occurring in SHH074, this was found together with H122N, L129M, and another 
drug resistance mutation rtM204V. Notably SHH074 was HBsAg- throughout the 
study and experienced full suppression of HBV by the end of the study.  The 
rtM204I mutation was found in isolate SHH148, at the 18 month time-point. 
Isolate SHH053A belonging to Genotype E had only one mutation in the Pol 
region, H122I. The isolate belonging to subgenotype D3, SHH173 had two Pol 
mutations namely, H122L and L129N. However these mutations are poorly 
described and their effects remain unknown.  
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CHAPTER 4: DISCUSSION 
 
This was an 18 month long follow-up study in HIV-infected Lam-treatment naïve 
participants at a rural hospital in the Mpumalanga province of South Africa 
(RSA), participants qualified for ART at initiation. Blood samples were collected 
at baseline (treatment-naïve) , for this serological profiling of HBsAg, HBeAg, 
HBcAg, anti-HBs, anti-HBe, anti-HBc, ALT levels, weight, BMI, CD4+ counts 
and HIV-viral-loads were tested and recorded. Serological results of the HBs, 
HBe and anti-HBc antigens and antibodies were available for all follow-up time 
points. ALT scores and HIV indicators of immune reconstitution were not 
available at follow-up. Viral-load quantification and PCR amplification were 
carried out on blood samples from follow-up and used to determine viral-
suppression, and mutations in the BCP/PreC, complete S and Pol regions, which 
were also used in genotypic profiling. These regions were analysed to determine 
the molecular evolution of HBV isolates from HIV-infected Lam-treated study 
participants over an 18 month period. HBV is largely transmitted during 
childhood in sub-Saharan Africa, therefore, HBV and HIV are not contracted 
simultaneously. Studies of this nature are important, not only because HBV is 
endemic to sub-Saharan Africa, but also because of the high prevalence of 
HBsAg-negative and HBeAg-negative HBV infections in the region.  
 
 
4.1 Follow-up visit participation 
A minimum of 12% loss to follow-up was found at all consecutive follow-up 
time-points affecting the amount of molecular data generated. Auodjane et al., 
2014 also document low retention rates of participants in their 1-year study in 
sub-Saharan Africa, their study had a 72% return to follow-up at 6 months and a 
41% return at 12 months.  
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4.2 Demographic, Clinical, Serological and Virological Characteristics 
In the baseline study by Bell et al. 2012 it was found that the HBsAg+ group had a 
higher prevalence of liver fibrosis based on APRI scores conducted, these could 
not be determined for  follow-up, samples as  no liver biochemistry results were 
recorded at follow-up. A significant clinical characteristic was a higher baseline 
weight in the HBsAg+ positive group compared to the HBsAg- group (Table 3.2). 
When comparing baseline ALT levels of the FS and NS groups it was found that 
ALT levels were significantly higher in the NS group (Table 3.4 and Figure 3.4).  
 
 
4.3 HBsAg-positive versus HBsAg-negative 
All participants who were HBsAg+ were  expected to lose the HBsAg within 18 
months of Lam treatment, as HBsAg sero-clearance is a  goal of treatment (WHO, 
2015). All HBsAg+ group participants had detectable HBV DNA at the end of the 
study, therefore HBsAg positivity at any time is an indication that the HBV-
infection has not cleared.  Of these HBsAg+ participants 28.2% remained 
HBsAg+ at the last follow-up (Table 3.3). Although seven participants lost the 
HBsAg during the study, their viral-loads remained comparable to when they 
were HBsAg+. Similar findings were observed in a study carried out on HBV 
subgenotype A1 in Malawi, which found that participants that were HBsAg at any 
point during the study were unable to clear HBV DNA, moreover HBV viral-
loads were similar during HBsAg positivity and HBsAg negativity in these 
participants (Aoudjane et al., 2014).  
 
 
A high frequency, (48.72%) of HBsAg negativity was found in this study cohort 
of HBV-HIV co-infected participants which has been previously reported in this 
region (Mphahlele et al., 2006). When an immune-compromised individual has an 
active HBV-infection in the absence of HBsAg, this could be due to the formation 
of immune-complexes between anti-HBs and HBsAg which explains the high 
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prevalence of HBsAg- in HIV-infected Southern Africans (Mphahlele et al., 
2006). If more is understood regarding the natural course of HBsAg-negative 
HBV infection in HIV+ participants, this will lead to improved care and 
management of HBV-HIV co-infected participants.  The absence of HBsAg is 
commonly used as an indicator of no active HBV infection (Terrault et al., 2015; 
WHO, 2015), yet this study has shown that high HBV-DNA levels persist in 
HBsAg- participants. Thus, HBsAg sero-clearance may be a poor indicator of 
resolution of the HBV infection, in a large percentage of individuals, who are 
otherwise considered uninfected or cured.  Undetected HBV infection, may 
progress to HCC, cirrhosis or ESLD. HBV DNA has been found in HBsAg- 
individuals suffering from HCC (Pollicino et al., 2004). Following the 
development of HCC patients may be exposed to immune-suppressive 
chemotherapeutic agents that could further exacerbate the HBV, as well as HIV 
infection.  
 
 
4.4 Full Suppression and No Suppression Group Comparison 
Baseline HBsAg negativity was a predictor of full suppression, only participants 
in the HBsAg- group experienced a full suppression (Table 3.4 and Figure 3.6). 
The viral suppression observed in this group occurred after 12 months of initiating 
Lam, which is in accordance with the findings of a similar study by Hafkin et al. 
2014. Therefore it may be beneficial to use 12 months as a better indication 
response to treatment. Incomplete viral suppression was associated with higher 
baseline HBV viral-loads (Hafkin, 2015) however in the present study baseline 
HBV viral-loads between the FS and NS were similar. An important outcome in 
anti-HBV therapy in CHB infected individuals is to reduce HBV viral-loads, this 
leads to a decreased risk of CHB disease sequelae and liver damage.  A median of 
56.06% (IQR: [-100%] – [+23.46%]) decrease in HBV viral-loads was 
experienced by 34 participants in the present study.  
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4.5 Virologic Breakthrough Positive and Negative Groups  
Of the 20 participants in the NS group, ten experienced a VBT. Although other 
studies have found that the baseline HBV-DNA level is the most important factor 
associated with VBT in Lam treated participants (Chae and Hann, 2007), the HBV 
viral-loads  between the NS VBT+ and NS VBT-  groups were similar at baseline. 
This study found that 70% of NS VBT+ participants were HBsAg- throughout, all 
these participants fully suppressed HBV before experiencing a VBT. This study 
was limited to an 18-month period post-initiation of ART, the HBsAg- group that 
maintained full-suppression of HBV by the end of the study may  experience a 
VBT at a later stage, since this study found that full suppression of HBV may be 
followed by a VBT in HBsAg- participants. Therefore VBT is possible in HBsAg-
negative participants that have cleared infection which was shown in the present 
study, therefore, continuous monitoring of HBsAg- HBV-infection in HIV-
positive participants is required at regular intervals.   
 
 
4.6 Genotyping  
4.6.1 Genotyping using BCP/PreC sequences  
Bartholomeusz & Schaefer 2004 found nucleotides or nucleotide polymorphisms 
specific to certain genotypes using the BCP/PreC region, using positions 1762, 
1764, 1809-1812, 1814-1816, 1858, 1862, 1888 and 1896. Using these loci 
SHH053A was found to have a non-A HBV infection, and  was later confirmed to 
have a Genotype E infection by complete S-region phylogenetic analysis, this 
genotype prevails in Western and Central Africa (Kramvis, Kew and François, 
2005). However further investigation of this genotype is required to improving 
understanding of it. BCP/PreC loci analysis indicated SHH173A had a 
subgenotype A1 HBV infection, however, this contradicted the findings of the 
complete S region that indicated that this was a subgenotype D3 isolate. The 
remaining 90.91% of sequences in the study belonged to subgenotype A1, this is 
in accordance with previous findings from the region which demonstrated that 
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subgenotype A1 is the predominant strain found in this region in both 
monoinfected (Kimbi et al, 2004) and HBV/HIV co-infected individuals 
(Makondo, Bell and Kramvis, 2012). 
 
Although genotyping by BCP/PreC sequencing is a simple and inexpensive 
method of genotyping this method cannot distinguish between genotypes D and E, 
since these regions share great homogeneity in the X and and PreC/Core ORFs 
However, this region can be used for differentiating genotype A from other 
genotypes and subgenotype A1 from A2.  The advantage of using this region is 
that the BCP/PreC region is a shorter region that easily amplifies during PCR 
yielding more amplicon for genotyping in comparison to the complete S or full 
genome because these regions are quite large 1200 – 3200 nucleotides long.    
 
4.6.2 Complete S Phylogenetic Analysis  
Fewer amplicon were generated by PCR amplification of the complete S-region 
(47 sequences), compared to the BCP/PreC region which yielded 77 sequences. 
These 47 complete S region sequences were used to construct a neighbour-joining 
phylogenetic tree including genotypes and subgenotypes A-F, which was used to 
determine the genotype or subgenotype of isolates in this study.  
 
Phylogenetic analysis revealed that two isolates (SHH053A and SHH173A) in 
this study did not belong to subgenotype A1 at baseline rather, these isolates 
belonged to genotype E and subgenotype D3, respectively. SHH053A had the 
characteristic genotype E 3 nucleotide deletion (Norder, Couroucé and Magnius, 
1994)  in the PreS1 region from nt 2853 – 2855 (Table 3.11). However the 33 nt 
deletion characteristic of genotype D was not found in isolate SHH173A 
(Kramvis, 2014) and a bootstrap value <65% was found for this isolate in relation 
to the subgenotype D3 reference sequences used in the phylogenetic tree (Figure 
3.8). This could be explained by the presence of a mixed infection or a 
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recombinant genotype A/D strain however full length amplification or cloning and 
sequencing is required to determine this . Previous studies from sub-Saharan 
Africa have documented the existence of these two genotypes in this region, 
however, subgenotype A1 is the predominant strain found in this region (Kimbi et 
al., 2004), whereas genotype D is found in northern Africa and genotype  E is 
found predominantly in western Africa (Kramvis and Kew, 2007; Kimbi et al,. 
2004). Other than isolates SHH053A and SHH173A all HBV other isolates 
belonged to subgenotype A1.   
 
Previous studies documented that infection with HBV genotype-A is associated 
with an increased risk of developing HCC in black Africans than those infected 
with non-A genotypes (Kew et al., 2005). There is also lower frequency  of 
HBeAg-positivity in individuals infected with subgenotype  and this is highly 
significant in carriers younger than 30 years of age (Kramvis and Kew 2007; 
Tanaka et al., 2004).  In comparison to genotype D, sera from both the HBeAg 
and anti-HBeAg positive phases have lower HBV viral-loads in subgenotype A1 
infections (Tanaka et al., 2004). Both genotype D and E found in Africa have 
different mutations resulting in the anti-HBe seroconversion in comparison to 
subgenotype A1 (Kramvis and Kew 2007).       
 
Phylogenetic trees, such as the one constructed during this study, use specific 
algorithms to determine the evolutionary relatedness of sequences to each other 
and reference sequences (McCormack and Clewley, 2002). The construction and 
analysis of phylogenetic trees are more labour intensive and require specialised 
skills in comparison to the method employed using BCP/PreC analysis. However 
a major advantage of using this type of genotyping method analyses a larger 
region of the HBV genome than the limited amount loci analysed in the 
BCP/PreC region, this lends more statistical support to the complete S-region 
phylogenetic analysis method. Therefore the complete S region is more 
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informative but if a mixed infection or recombinant infection is suspected, cloning 
and sequencing of the complete HBV genome is required.    
 
4.7 Molecular Characteristics  
Sequence data was used to molecularly characterise the BCP/PreC and complete S 
genes of the HBV genome in 39 HBV-HIV co-infected adults at various times 
before and after initiation of a Lam-containing ARV regimen. The BCP/PreC and 
complete S regions were characterised at each time point, followed by the 
construction of a phylogenetic tree using complete S sequences to determine the 
HBV genotypes and subgenotypes present in this study. Each region was 
subsequently analysed for various mutations that affect disease progression, 
response to treatment, in addition detection- or immune-escape variants were 
determined. 
 
4.7.1 BCP/PreC Mutations 
There were a total of 78 sequences yielded from PCR amplification of the 
BCP/PreC region. Of these 24 sequences were from baseline, 15 from time-point 
“B”, 14 from “C”, 13 from “D”, lastly 12 from time-point E. Mutations in this 
region affect the production of HBcAg and HBeAg. The A1762T/G1764A double 
mutation appeared in six HBeAg- isolates and one HBeAg+ (Table 3.10). This 
down regulates the production of PreC/C mRNA transcripts,  therefore decreasing 
the amount of HBeAg produced, however, viral replication is increased as a result 
of the increased pgRNA packaging (Takahashi et al. 1995; Buckwold et al. 1996). 
An increased risk associated with this mutation is it contribution to the 
development of HCC by an unknown mechanism (Baptista, Kramvis and Kew, 
1999). This mutation has also been implicated in an increased progression to liver 
disease (Buckwold et al., 1996; Baptista, Kramvis and Kew, 1999), this can be 
attributed to the increase in viral replication which leads to an increase in viral-
load. Four  isolates had the double mutation in the BCP/PreC region this was 
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found together with the T1753C was found in three of these isolates isolates, this 
is sometimes referred to as the triple mutation. T1753C has been described as an 
HCC marker and is often found in HBeAg- individuals or those with active liver 
disease (Pujol et al., 2009).  
 
Subgenotype A1 has a distinct Kozak sequence namely, 1809TCAT1812(Baptista, 
Kramvis and Kew, 1999; Kramvis et al., 2008), which is the region located 
immediately upstream of the PreC initiation codon (Tong et al., 1992). Most 
76.62% isolates in this study had the 1809TCAT1812 Kozak sequence (Table 3.10). 
Mutations in the Kozak region, nt 1809 -1812 (numbering from the EcoR1 site) 
negatively affect HBeAg production at a translational level (Kozak, 1986). 
HBeAg may be abolished when three mutations are found within this sequence 
(Ahn et al., 2003), this is postulated to result in earlier seroconversion to HBeAg-. 
A leaky scanning mechanism arises as a result of a mutation in the Kozak region, 
causing a reduction in HBeAg production (Ahn et al 2003). The majority,  of 
HBV strains circulating in sub-Saharan Africa contain double or triple mutations 
within the Kozak region, this contributes to the high prevalence of HBeAg 
negativity in the strains found in this region of Africa ( Kramvis and Kew, 2007). 
Other mutations such as TCCT, TCTT, TTCT, and TCAC have also been 
implicated in HBeAg translational impairment. When mutations in the Kozak 
region are coupled with A1762T/G1764A double mutation HBeAg production is 
abolished (Ahn et al., 2003).  
 
Mutations at PreC start codon nt 1814-1816 (from the EcoR1 site) were found in 
seven isolates in this study (Table 3.10). Mutations in this region prevent initiation 
of HBeAg translation (Laras et al., 1998), therefore reducing the production of 
HBeAg. Isolate SHH274A had an 1814ACG1816 mutation despite being HBeAg+ at 
the time (Table 3.10), this could be attributed to a mixed infection with HBV, 
whereby PreC mutant strains and wild-type strains are present in the same host, 
with the wild-type being the non-dominant strain thus was not amplified during 
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PCR but provided sufficient production of HBeAg which was detected upon 
serology testing for this antigen.  
 
Another BCP/PreC mutation affecting expression of HbeAg expression at the  
post-translational level is the G1862T transversion mutation, which was found in  
22% BCP/PreC sequences. Previous studies (Kramvis et al.,1997; Kramvis et al., 
1998) found a higher frequency of this mutation in subgenotype A1, from sub-
Saharan Africa. It is the HBeAg precursor that is affected by this mutation, 
whereby this missense mutation inhibits signal peptide cleavage (Chen et al., 
2008). This results in the inhibition of HBeAg secretion thus causing an 
accumulation of HBeAg and its precursors in the endoplasmic reticulum and 
Golgi (Chen et al., 2008). HBeAg may be reduced to undetectable levels when 
G1862T is found together with the A1762T/G1764A double mutation, this was 
found in isolate SHH221A. 
 
The G1888A mutation, found in nine HBeAg- isolates and two HBeAg+ isolates 
(Table 3.10), which prematurely introduces a start codon upstream from the core 
start codon and thus impairs translation of HBcAg (Kimbi, Kew and Kramvis, 
2012). This mutation is unique to subgenotype A1.  The G1896A mutation, like 
loci 1862 is found in the encapsidation signal (ε) of the PreC/C region. This 
mutation introduces a premature stop codon truncating the HBeAg, results in the 
abolishment of HBeAg production at the translational level (Carman et al., 1989). 
This mutation was found together with C1858T in two isolates.   This mutation is 
precluded in the presence of 1858C because this would interfere with the 
secondary structure of the encapsidation signal (ε) and prevent viral replication 
(Li et al., 1993; Lok, Akarca and Greene, 1994). In genotype D the development 
of the G1896A stop codon and the A1762T/G1764A double mutation in the 
BCP/PreC region, result in the anti-HBeAg sero-conversion (Kramvis and Kew, 
2007).     
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4.7.2 Complete S mutations 
The complete S-region encodes the three HBV viral surface proteins, LHBs, 
MHBs and SHBs using the PreS1, PreS2 and S ORFs. These surface proteins are 
integral to HBV viral attachment to hepatocytes and are pivotal to virus 
assembly(Prange and Streeck, 1995; Glebe and Urban, 2007). The HBsAg 
contains the crucial ‘a’ determinant, this is the region of HBsAg targeted by 
antibodies as it contains major B and T-cell epitopes. Mutations in this region may 
result in vaccine-escape, detection-escape, immune-escape or  clinical 
manifestations, such as reactivation, VBT or HCC and liver disease progression 
(Fan et al., 2001; Sugauchi et al., 2003). In the present study 47 complete S 
sequences were generated, of these 25 sequences were from baseline isolates.   
 
4.7.2.1 PreS1 Mutations 
Numerous PreS1 mutations, S5T/N/L, F25L, I48V/T, L85V/M, V88A/L, 
T90V/L/A/K and P94T within the neutralising epitope and those involved in 
hepatocyte attachment were observed during this study.  
  
4.7.2.2 PreS2 Mutations 
The M1I/L PreS2 stop codon mutation found during this study (Table 3.10) 
prevents the initiation of translation of MHBs, thereby preventing its production. 
A mutation unique to subgenotype A1, L32H was observed intermittently during 
the study.  The Q10R mutation located in the major antigenic region of PreS2, 
was observed at baseline and the last follow-up. This mutation affects B-cell, T-
cell and cytotoxic T lymphocyte epitopes reducing the ability of antibody binding 
thereby avoiding the neutralising effect of antibodies raised against this antigen 
(Paulij et al., 1999). 
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4.7.2.3 HBsAg Mutations 
The T118K mutation located in the major hydrophilic loop of HBsAg, was found 
in 12.5% of HBsAg- individuals which has been previously reported in Northern 
Europe. (Salpini et al., 2015; Caligiuri et al., 2016) The vaccine induced immune-
escape mutation Q129R, located in the crucial ‘a’ determinant region(Lazarevic, 
2014; Caligiuri et al., 2016), was found in 12.5% of HBsAg- isolates, resulting in 
diagnostic failure by currently available HBsAg detection assays(Raimondo et al., 
2008). The HBsAg region had fewer mutations than the PreS1 and PreS2 regions, 
and was found to be a highly conserved region. Two reactivation markers, V168A 
and S174N were found in two HBsAg- isolates however both were from the FS 
group therefore did not experience a re-activation of HBV infection. However 
HIV immune suppression is the associated cause of reactivation in the presence of 
these mutations (Gerlich et al., 2010).   
 
4.7.2.4 PreS1/PreS2 Deletion Mutants 
Seven isolates in this study were found to have PreS1/PreS2 deletions (Table 
3.11), including the characteristic genotype E 3 nt deletion found in the PreS1 
region of SHH053A. Most PreS2 deletions found in this study occurred in the 
major B and T cell epitopes and/or the polymerized serum albumin binding sites. 
PreS deletions in the S-region are possibly involved in the development of occult 
infection as these deletions can affect HBsAg expression synthesis and secretion 
(Chen et al., 2012; Huang et al., 2014). PreS deletions are more frequently found 
in HBV-HIV co-infection (Audsley et al., 2010; Makondo, Bell and Kramvis, 
2012) and HCC patients infected with HBV subgenotypeA1 (Kew et al., 2005). 
The prevention of HBsAg secretion results in the accumulation of this protein in 
ER of hepatocytes. This leads to oxidative stress resulting in DNA damage, which 
contributes to the development of HCC (Chen et al., 2006; Caligiuri et al., 2016). 
Transcriptional activators of HBV promoters have also been implicated in the 
development of HCC, as a result of PreS deletion mutants(Hildt et al., 1996). 
4.7.3 Polymerase Mutations 
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The HBV polymerase enzyme is integral to the replication cycle moreover this 
region is the target of many drugs. The lack of proof-reading of the polymerase 
results in an error rate of 1 x 10-5 - 1 x 10-7 nucleotide change per site per year 
(Girones and Miller, 1989). Despite the introduction of TDF in South Africa, Lam 
remains widely used in the treatment of HBV- and/or HIV-infection, as it is more 
affordable than TDF.  All strains in this study were receiving the nucleoside 
analogue Lam, this drug is widely used despite the development of HBV 
resistance mutations. The YMDD catalytic site is vital to reverse transcription 
function, this is the specific site targeted by Lam. Anti-viral agents may cause 
selection pressure leading to drug mutations, caused by dominant quasi-species 
strains (Caligiuri et al., 2016). Moreover, mutations in the Pol region may affect 
the overlapping S-region, causing vaccine-, immune- or detection-escape 
mutations (Sheldon et al., 2005).    
 
Mutations rtS105T, rtH122I/L/N, rtQ125E and rtL129V/N are poorly described 
and their effects are yet to be elucidated. The rtE1D mutation was found in 
13.33% of HBV isolates from this study, however the resultant amino-acid change 
does not lead to any functional changes of the polymerase, given the structural 
and chemical similarities between glutamic acid (E) and aspartic acid (D) 
(Makondo, Bell and Kramvis, 2012). The Q125E mutation was the only mutation 
found in HBV isolates from the NS VBT+ group, occurring once at baseline.  
 
Two drug resistance mutations, rtL180M and rtM204V/I, were found in this 
study(Table 3.10). These mutations may cause vaccine escape mutations in the 
overlapping S-region and prevent secretion of HBsAg (Sheldon et al., 2005). The 
rtM204I/V mutation is found within the YMDD (tyrosine-methionine-aspartate-
aspartate) region, located in the C-domain of HBV polymerase. Spontaneous 
mutations in the YMDD region, have been associated with liver cirrhosis and 
HCC (Yang et al., 2013; Caligiuri et al., 2016). In addition a lower rate of VBT 
has been reported in HBV isolates from treatment-naïve individuals without 
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YMDD mutations in comparison to isolates with naturally occurring YMDD 
mutations (Yang et al., 2013). The rtM204V mutation reduces replication in vitro, 
however compensation mutations such as rtL180M develop, to restore replication 
competence (Delaney et al., 2003).   
 
In this study the rtM204I mutation, was the only Pol mutation found in isolate 
SHH148E whilst the rtM204V + rtL180M were found together in HBV isolated 
from SHH074A. Previous studies from sub-Saharan Africa have found the 
rtM204I mutation in the HBV genome of therapy-naïve HBV-HIV co-infected 
individuals (Selabe et al., 2009) whereas in the present study this mutation was 
found after 18 months of Lam treatment in the isolate SHH074 from the NS VBT- 
group.  
 
4.8 Limitations to this Study 
Inconsistent return for follow-up was a major limitation to the study. Due to 
financial constraints and a shortage of personnel, it was not possible to obtain 
liver biochemistry data and CD4+ counts for the time-points post-initiation of 
ART. This data would have assisted us in understanding at what time-point if at 
all, there was the development of liver fibrosis, cirrhosis or HCC and if the CD4+ 
count could be related to disease progression. Changes in CD4+ count could 
affect the suppression and virologic breakthrough. Availability of information 
such as HIV viral-loads and CD4+ counts would have assisted us in understanding 
why some participants were able to successfully clear the virus. One of the other 
limitations of the study is that participants did not return to follow-up, this could 
possibly reflect a poor adherence as they may not have had access to medication. 
The low statistical power of the follow-up molecular analysis was also influenced 
by low viral-loads, this also decreases the amplicon generated when amplifying 
larger regions such as the complete S region or complete genome. 
CHAPTER 5 CONCLUSION 
88 
 
 
There are a limited number of studies from this high endemicity area on the 
changes that occur during anti-viral treatment and the effect it has on HBV over 
time. Therefore the present study was undertaken to investigate the effect of Lam 
on HBV in HIV-infected individuals from a sub-Saharan African perspective. The 
BCP/PreC and complete S-regions were amplified and sequenced to characterise 
molecular evolution of HBV during ART in comparison to pretherapy. 
 
Sequence heterogeneity is expected since HBV Pol lacks proof-reading activity, 
various studies have described the effect of mutations and their relevance in HBV 
infection(Bell, 2013; Kramvis, 2014; Matthews et al., 2014; Yousif et al., 2014; 
Colson et al., 2015). The present study objectives to identify the genotypes or 
subgenotypes were achieved as well as monitoring the effect of Lam in terms of 
viral suppression.BCP/PreC, complete S and Pol mutations were identified and 
correlated to their clinical relevance.  
 
The current study found that serum HBV DNA persisted regardless of HBsAg 
clearance (HBsAg+ group). Baseline HBV DNA levels in the HBsAg-negative 
group were comparable to those in the HBsAg-positive group, although higher 
levels of VBT’s occurred in the HBsAg-negative group. This study re-enforces 
the need for NAT to detect HBV infection, which has already been proposed by 
others (Raimondo et al., 2008; Bell et al., 2012; Yousif et al., 2014; González et 
al., 2015), especially in high-risk populations, such as HIV-positive individuals 
prior to and post initiation of Lam-containing ART. There are severe clinical 
consequences to undetected HBV-infection, such as an increased risk of HCC, 
more common in subgenotype A1, which was the predominant strain isolated in 
this study, (Kew et al., 2005).  
The need for treating HBV-infection in this HIV burdened population using 
Tenofovir is preferred considering that mutants identified in this study are also 
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sensitive to  this drug(Mphahlele et al., 2006; Matthews et al., 2010; Bell et al., 
2012; Makondo, Bell and Kramvis, 2012).  Unfortunately, both NAT testing and 
TDF treatment are costly measures that may not be conducive to developing or 
third world countries. Furthermore, molecular analysis may be required to detect 
resistance mutations or response to treatment, which adds to the cost of HBV 
management. Sub-Saharan Africa is an area of HBV and HIV endemicity, with a 
significantly higher prevalence of HBV in HIV-infected individuals (Thio et al., 
2002). Subgenotype A1 is the most prevalent strain found in sub-Saharan Africa 
(Bowyer and Sim, 2000; Kimbi, Kramvis and Kew, 2004). Disease progression, 
response to treatment and the development of mutations differ among the various 
genotypes or subgenotypes, thus studies specific to genotypes or subgenotypes  
are necessary.  
 
This study showed that ALT levels are an important predicator of HBV 
suppression, because lower ALT levels were found in the FS group. ALT levels 
are also indicative of the severity of disease, which may correlate to the abilty of 
the drug to suppress the virus, patients with persistently elevated ALT levels are 
an indication the treatment might be failing, allowing for lengthy periods of HBV 
replication leading to high viral-loads, which is known to increase progression of 
liver disease (Pollicino et al., 2004; Coffin et al., 2014; Kwak and Kim, 2014).    
 
The most significant finding of the study was that participants that achieved 
control of HBV infection by fully suppressing the virus following treatment was 
associated with HBsAg loss. However VBT was still possible. This study can be 
repeated in a larger study population thereby increasing the amount of sequence 
data generated. Longer studies within such a population will also allow more 
indepth insight into drug resistence emergence patterns and the long-term effects 
of Lam and HIV on HBV infection. 
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Table 3.10 Molecular Characteristics of the BCP/PreC Region of HBV isolated from HBeAg+ 
and HBeAg- 
Group Mutation 
Participant  Time-point 
Number A B C D E 
HBeAg 
Negative  
A1762T/G1764A 
SHH148 + - - - + 
SHH221 + NS - - - 
SHH264 + NS NS NS NS 
SHH274 + - - - - 
SHH300 - - NS - + 
1809GCAC1812 
SHH001 - - + NS NS 
SHH016 + - NS - - 
SHH032 + NS NS NS NS 
SHH042 + + - + - 
SHH053 + - - - - 
SHH070 - - - + - 
SHH221 + - - - - 
SHH274 + - - - - 
1809TCAC1812 SHH148 + - - - + 
1809TCCT1812 SHH240 + - - - - 
1809ACAT1812 SHH300 + - NS - - 
1814CTG1816 
SHH001 + - - NS NS 
SHH070 + - - - - 
SHH221 + NS - - - 
1814AAG1816 SHH148 + - - - + 
1814ACG1816 SHH300 + - NS - + 
C1858T 
SHH016 + - NS - - 
SHH042 + - - - - 
SHH053 + + - - - 
SHH070 - + - + - 
G1862T 
SHH029 - + NS NS NS 
SHH042 - - + - - 
SHH053 + - + - - 
SHH070 - - + - - 
SHH071 NS NS + - NS 
SHH074 NS + NS NS NS 
SHH156 + + + NS - 
HBeAg 
Negative  
G1862T 
SHH173 + NS - NS NS 
SHH219 + - NS NS NS 
SHH221 + NS - - - 
SHH246 + NS NS NS NS 
A1888G 
SHH001 + - - NS NS 
SHH016 + - NS - - 
SHH032 + NS NS NS NS 
SHH042 + - - + - 
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Table 3.10 Molecular Characteristics of the BCP/PreC Region of HBV isolated from HBeAg+ 
and HBeAg- 
Group Mutation 
Participant  Time-point 
Number A B C D E 
HBeAg 
Negative  
A1888G 
SHH053 + - + - - 
SHH148 + - - - + 
SHH221 - NS + - - 
SHH264 + NS NS NS NS 
SHH300 + - NS - + 
A1888T SHH070 - - + - - 
G1896A 
SHH016 + - NS - - 
SHH032 + NS NS NS NS 
SHH042 + - - - - 
HBeAg 
Positive 
A1762T/G1764A SHH180 + - - - - 
G1764A SHH274 + - - - - 
1809GCAC1812 SHH159 + - - - - 
1809TTCT1812 SHH180 + - - - - 
1809TCTT1812 SHH193 + - NS NS NS 
1814ACG1816 SHH274 + - - - - 
G1862T 
SHH002 - + - - - 
SHH159 - + - - - 
SHH193 NS + NS NS NS 
A1888G 
SHH180 + - - - - 
SHH274 + - - + - 
